KR102461669B1 - Antiviral agent for treating or alleviating rhinovirus - Google Patents
Antiviral agent for treating or alleviating rhinovirus Download PDFInfo
- Publication number
- KR102461669B1 KR102461669B1 KR1020200023264A KR20200023264A KR102461669B1 KR 102461669 B1 KR102461669 B1 KR 102461669B1 KR 1020200023264 A KR1020200023264 A KR 1020200023264A KR 20200023264 A KR20200023264 A KR 20200023264A KR 102461669 B1 KR102461669 B1 KR 102461669B1
- Authority
- KR
- South Korea
- Prior art keywords
- virus
- antiviral agent
- present
- agent according
- symptoms
- Prior art date
Links
- 239000003443 antiviral agent Substances 0.000 title claims abstract description 115
- 241000709661 Enterovirus Species 0.000 title claims abstract description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 38
- 241000241413 Propolis Species 0.000 claims abstract description 22
- 229940069949 propolis Drugs 0.000 claims abstract description 22
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 21
- 240000003553 Leptospermum scoparium Species 0.000 claims abstract description 21
- 235000016887 Leptospermum scoparium Nutrition 0.000 claims abstract description 21
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 21
- 235000012907 honey Nutrition 0.000 claims abstract description 21
- 241000208140 Acer Species 0.000 claims abstract description 20
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 20
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 20
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 20
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000006188 syrup Substances 0.000 claims abstract description 20
- 235000020357 syrup Nutrition 0.000 claims abstract description 20
- 235000010447 xylitol Nutrition 0.000 claims abstract description 20
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 20
- 229960002675 xylitol Drugs 0.000 claims abstract description 20
- 239000000811 xylitol Substances 0.000 claims abstract description 20
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 19
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 19
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000004863 Frankincense Substances 0.000 claims abstract description 19
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 19
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 19
- 239000011718 vitamin C Substances 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 14
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 10
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 10
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 10
- 239000011425 bamboo Substances 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 7
- 239000003610 charcoal Substances 0.000 claims description 3
- 244000082204 Phyllostachys viridis Species 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 103
- 201000010099 disease Diseases 0.000 abstract description 90
- 230000000694 effects Effects 0.000 abstract description 29
- 239000000843 powder Substances 0.000 abstract description 16
- 239000000284 extract Substances 0.000 abstract description 14
- 239000007788 liquid Substances 0.000 abstract description 4
- 241000700605 Viruses Species 0.000 description 150
- 208000024891 symptom Diseases 0.000 description 76
- 238000012360 testing method Methods 0.000 description 47
- 230000000840 anti-viral effect Effects 0.000 description 42
- 230000003612 virological effect Effects 0.000 description 40
- 208000002193 Pain Diseases 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 35
- 206010061218 Inflammation Diseases 0.000 description 30
- 230000004054 inflammatory process Effects 0.000 description 30
- 230000006872 improvement Effects 0.000 description 28
- 208000007514 Herpes zoster Diseases 0.000 description 25
- 239000012085 test solution Substances 0.000 description 25
- 238000005259 measurement Methods 0.000 description 20
- 230000009467 reduction Effects 0.000 description 20
- 230000009385 viral infection Effects 0.000 description 20
- 206010012438 Dermatitis atopic Diseases 0.000 description 18
- 208000036142 Viral infection Diseases 0.000 description 18
- 201000008937 atopic dermatitis Diseases 0.000 description 18
- 239000003814 drug Substances 0.000 description 17
- 206010022000 influenza Diseases 0.000 description 17
- 210000003491 skin Anatomy 0.000 description 17
- 241000710188 Encephalomyocarditis virus Species 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 238000006386 neutralization reaction Methods 0.000 description 16
- 241000711484 Transmissible gastroenteritis virus Species 0.000 description 15
- 241001364929 Havel River virus Species 0.000 description 14
- 206010020772 Hypertension Diseases 0.000 description 14
- 201000004681 Psoriasis Diseases 0.000 description 14
- 231100000135 cytotoxicity Toxicity 0.000 description 14
- 230000003013 cytotoxicity Effects 0.000 description 14
- 238000010790 dilution Methods 0.000 description 14
- 239000012895 dilution Substances 0.000 description 14
- 239000006187 pill Substances 0.000 description 14
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 206010012601 diabetes mellitus Diseases 0.000 description 13
- 201000010374 Down Syndrome Diseases 0.000 description 12
- 206010044688 Trisomy 21 Diseases 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 210000001508 eye Anatomy 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 12
- 210000003205 muscle Anatomy 0.000 description 12
- 206010047642 Vitiligo Diseases 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 208000023275 Autoimmune disease Diseases 0.000 description 10
- 206010051290 Central nervous system lesion Diseases 0.000 description 10
- 208000026350 Inborn Genetic disease Diseases 0.000 description 10
- 230000036772 blood pressure Effects 0.000 description 10
- 230000001684 chronic effect Effects 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 201000006938 muscular dystrophy Diseases 0.000 description 10
- 206010011385 Cri-du-chat syndrome Diseases 0.000 description 9
- 208000012239 Developmental disease Diseases 0.000 description 9
- 206010015150 Erythema Diseases 0.000 description 9
- 206010020751 Hypersensitivity Diseases 0.000 description 9
- 208000001804 Monosomy 5p Diseases 0.000 description 9
- 230000007815 allergy Effects 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 208000016361 genetic disease Diseases 0.000 description 9
- 208000007565 gingivitis Diseases 0.000 description 9
- 208000037797 influenza A Diseases 0.000 description 9
- 230000003902 lesion Effects 0.000 description 9
- 241001330002 Bambuseae Species 0.000 description 8
- 208000015114 central nervous system disease Diseases 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 206010040882 skin lesion Diseases 0.000 description 8
- 231100000444 skin lesion Toxicity 0.000 description 8
- 206010068319 Oropharyngeal pain Diseases 0.000 description 7
- 201000007100 Pharyngitis Diseases 0.000 description 7
- 208000003251 Pruritus Diseases 0.000 description 7
- 208000036071 Rhinorrhea Diseases 0.000 description 7
- 206010039101 Rhinorrhoea Diseases 0.000 description 7
- 208000026935 allergic disease Diseases 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 230000035876 healing Effects 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 210000004400 mucous membrane Anatomy 0.000 description 7
- 201000009240 nasopharyngitis Diseases 0.000 description 7
- 206010039083 rhinitis Diseases 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 206010012289 Dementia Diseases 0.000 description 6
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 201000009151 chronic rhinitis Diseases 0.000 description 6
- 231100000321 erythema Toxicity 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 208000000509 infertility Diseases 0.000 description 6
- 230000036512 infertility Effects 0.000 description 6
- 231100000535 infertility Toxicity 0.000 description 6
- 230000027939 micturition Effects 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 206010029446 nocturia Diseases 0.000 description 6
- 210000001331 nose Anatomy 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 208000014644 Brain disease Diseases 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 208000000112 Myalgia Diseases 0.000 description 5
- 231100000263 cytotoxicity test Toxicity 0.000 description 5
- 210000003811 finger Anatomy 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 210000004247 hand Anatomy 0.000 description 5
- 208000002672 hepatitis B Diseases 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 210000002414 leg Anatomy 0.000 description 5
- 210000002752 melanocyte Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 206010063057 Cystitis noninfective Diseases 0.000 description 4
- 208000032274 Encephalopathy Diseases 0.000 description 4
- 208000001640 Fibromyalgia Diseases 0.000 description 4
- 208000007882 Gastritis Diseases 0.000 description 4
- 241000700721 Hepatitis B virus Species 0.000 description 4
- 201000006347 Intellectual Disability Diseases 0.000 description 4
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- 241000519995 Stachys sylvatica Species 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 201000003139 chronic cystitis Diseases 0.000 description 4
- 208000023652 chronic gastritis Diseases 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 208000037824 growth disorder Diseases 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 208000021760 high fever Diseases 0.000 description 4
- 230000001631 hypertensive effect Effects 0.000 description 4
- 239000011812 mixed powder Substances 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 208000013465 muscle pain Diseases 0.000 description 4
- 231100001083 no cytotoxicity Toxicity 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 230000003239 periodontal effect Effects 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 206010003645 Atopy Diseases 0.000 description 3
- 201000006082 Chickenpox Diseases 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000712431 Influenza A virus Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010029240 Neuritis Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000010332 Plantar Fasciitis Diseases 0.000 description 3
- 206010046980 Varicella Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 230000035487 diastolic blood pressure Effects 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 239000005417 food ingredient Substances 0.000 description 3
- 210000001061 forehead Anatomy 0.000 description 3
- 229940075000 frankincense extract Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 238000011866 long-term treatment Methods 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000007918 pathogenicity Effects 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 210000003501 vero cell Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 210000000707 wrist Anatomy 0.000 description 3
- 241000934067 Acarus Species 0.000 description 2
- 240000004144 Acer rubrum Species 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 206010011469 Crying Diseases 0.000 description 2
- 208000035976 Developmental Disabilities Diseases 0.000 description 2
- 206010012559 Developmental delay Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 206010017753 Gastric atony Diseases 0.000 description 2
- 208000002979 Influenza in Birds Diseases 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 description 2
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 2
- 206010028836 Neck pain Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241000721454 Pemphigus Species 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 206010064097 avian influenza Diseases 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 208000023819 chronic asthma Diseases 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 210000001752 female genitalia Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 230000007236 host immunity Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000037801 influenza A (H1N1) Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 2
- 229940124641 pain reliever Drugs 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000955 prescription drug Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 201000010740 swine influenza Diseases 0.000 description 2
- 229940061367 tamiflu Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 229940072651 tylenol Drugs 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 230000036318 urination frequency Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 235000004422 Acer negundo Nutrition 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000256837 Apidae Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 235000018062 Boswellia Nutrition 0.000 description 1
- 241000208229 Burseraceae Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 206010009152 Chronic tonsillitis Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010010755 Conjunctivitis viral Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000007984 Female Infertility Diseases 0.000 description 1
- 208000004067 Flatfoot Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241001481828 Glyptocephalus cynoglossus Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000430519 Human rhinovirus sp. Species 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010021928 Infertility female Diseases 0.000 description 1
- 206010022517 Intelligence increased Diseases 0.000 description 1
- 206010023509 Kyphosis Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- 206010061307 Neck deformity Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 241000269978 Pleuronectiformes Species 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 208000028872 Progressive muscular dystrophy Diseases 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010061494 Rhinovirus infection Diseases 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010044003 Tonsillar hypertrophy Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000005914 Viral Conjunctivitis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- 230000000311 effect on hepatitis Effects 0.000 description 1
- 230000002892 effect on hypertension Effects 0.000 description 1
- 230000000312 effect on influenza Effects 0.000 description 1
- 230000000073 effect on psoriasis Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 235000021018 plums Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000004935 right thumb Anatomy 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 208000000943 scapulohumeral muscular dystrophy Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 208000037851 severe atopic dermatitis Diseases 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/64—Sugar alcohols
- A23V2250/6422—Xylitol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/708—Vitamin C
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
라이노 바이러스 질환에 대하여 개선 효과를 발휘하는 항바이러스제를 개시한다. 본 발명에 따른 항바이러스제는, 메이플시럽, 죽력, 의이인, 자일리톨, 비타민C, 마누카꿀, 유향, 몰약 및 프로폴리스를 분말, 액상 또는 추출물 형태로 포함한다. Disclosed is an antiviral agent that exhibits an ameliorating effect on rhinovirus diseases. The antiviral agent according to the present invention includes maple syrup, tabasheer, uiin, xylitol, vitamin C, manuka honey, frankincense, myrrh and propolis in powder, liquid or extract form.
Description
본 발명은 항바이러스제에 관한 것으로, 더 상세하게는, 라이노 바이러스 질환에 대하여 증상의 개선 효과를 발휘하는 항바이러스제에 관한 것이다. The present invention relates to an antiviral agent, and more particularly, to an antiviral agent that exhibits an effect of improving symptoms for rhinovirus diseases.
병에 걸리지 않는 방법과 병을 극복하는 방법은 대부분 동일하다. 그 방법 중 하나는 병원성 미생물에 대한 면역력을 키우고, 병원성 미생물을 퇴치하는 것이다. 병원성 미생물은 바이러스, 세균, 진균, 모낭충(acarus folliculorum) 등을 포함한다. 이 가운데서, 특히 현대의학이 아직까지 정확히 그 정체를 파악하지 못하고 있고, 제대로 대응하지 못하고 있는 것이 바이러스이다. 본 발명자는 현대의학이 제대로 된 치료법을 제시하지 못하는 많은 질병이 바이러스의 감염으로 인해 발병한다고 추측하게 되었고, 본원 발명에 따른 항바이러스제를 많은 환자에게 적용하면서 이 추측이 사실임을 확인해 왔다. 따라서 앞으로 바이러스의 퇴치는 많은 질병을 극복하는 데 있어서 핵심적인 역할을 할 것이다.How not to get sick and how to overcome the disease are mostly the same. One of the methods is to increase immunity to pathogenic microorganisms and to fight pathogenic microorganisms. Pathogenic microorganisms include viruses, bacteria, fungi, acarus folliculorum, and the like. Among these, in particular, the virus is one that modern medicine has not yet accurately identified and has not been able to properly respond to. The present inventors have speculated that many diseases for which modern medicine cannot provide a proper treatment are caused by viral infection, and have confirmed that this assumption is true while applying the antiviral agent according to the present invention to many patients. Therefore, in the future, eradication of viruses will play a key role in overcoming many diseases.
한편, 바이러스는 그 특성상 병원성의 여부를 가리는 것이 어렵다. 백신이나 치료약을 찾아도 내성 바이러스의 발현이 쉬워서 지속적으로 치료효과를 나타내는 것이 매우 어렵다. 또한, 바이러스는 그 특성상 숙주의 세포 안에 기생하면서 숙주의 면역력이 강하면 세포 안에 잠복하여 면역세포와의 접촉을 피하고 숙주의 면역력이 약해지면 비로소 세포에서 나와 활동하면서 병원성을 발휘하게 된다. 따라서 세균이나 진균과 달리, 바이러스는 감염은 되었더라도 바이러스의 비활동성으로 인하여 병적 증상이 나타나지 않는 경우가 많아 바이러스의 병원성의 여부를 확인하기가 어렵다. 세균에 대한 정보가 부족한 시절에 결핵이나 나병이 유전병으로 오인된 적이 있었다. 일부 질병은 바이러스성 질병임에도 불구하고, 바이러스의 발견이나 바이러스의 병원성이 밝혀지지 않았다는 이유로 유전병이나 가족력에 기인한 질병으로 오인되고 있다. On the other hand, it is difficult to determine whether a virus is pathogenic due to its characteristics. Even if a vaccine or therapeutic agent is found, the expression of a resistant virus is easy, so it is very difficult to continuously show a therapeutic effect. In addition, viruses, by their nature, parasitize in the cells of the host, and if the immunity of the host is strong, dormant in the cells to avoid contact with the immune cells, and only when the immunity of the host is weakened, they come out of the cells and show pathogenicity. Therefore, unlike bacteria or fungi, viruses often do not show any pathological symptoms due to inactivity even though they are infected, making it difficult to determine whether the virus is pathogenic. At a time when information on bacteria was scarce, tuberculosis and leprosy were sometimes mistaken for hereditary diseases. Although some diseases are viral diseases, they are mistaken for a disease caused by a genetic disease or a family history because the discovery of the virus or the pathogenicity of the virus is not known.
바이러스는 살아 있는 세포 안에서 기생하고, 크기가 작고, 구조가 간단하여 돌연변이의 가능성이 매우 높다. 바이러스는 새로운 종류나 변종이 계속적으로 등장하기 때문에, 알려져 있는 종류보다 알려져 있지 않은 종류가 훨씬 더 많다. 신종 또는 변종 바이러스의 출현이 빈번하고 예측이 어렵기 때문에, 백신의 개발이 어렵다. 잦은 변종 바이러스의 등장으로 어렵게 개발된 항바이러스제도 지속적으로 치료효과를 발휘하기가 힘든 경우가 많다. Viruses are parasitic in living cells, and their small size and simple structure make them highly susceptible to mutation. Because new strains and strains are constantly emerging, there are far more unknown types than known types. Because the emergence of new or mutated viruses is frequent and difficult to predict, the development of vaccines is difficult. Due to the frequent appearance of mutated viruses, it is often difficult for antiviral drugs that have been developed with difficulty to continuously exhibit therapeutic effects.
종래, 항바이러스제는 바이러스의 종류별로 서로 다른 약제가 개발되어 적용되고 있다. avian 인플루엔자(influenza), severe acute respiratory syndrome, novel 인플루엔자(influenza), Middle East respiratory syndrome coronavirus 등의 바이러스성 질환들에 대해서도 개별 질환에 대해서만 특유의 효과가 있는 백신이나 치료제가 개발되고 있다. 그러나, 이러한 백신이나 치료제는 변종 바이러스나 새롭게 출현한 바이러스에 대해서는 약효를 발휘하지 못한다. Conventionally, different antiviral agents have been developed and applied for each type of virus. For viral diseases such as avian influenza (influenza), severe acute respiratory syndrome, novel influenza (influenza), and Middle East respiratory syndrome coronavirus, vaccines or therapeutic agents that are uniquely effective for individual diseases are being developed. However, these vaccines or therapeutic agents are not effective against mutated viruses or newly emerged viruses.
본원 발명의 목적은 라이노 바이러스 질환의 증상을 개선할 수 있는 항바이러스제를 제공하는 데 있다. An object of the present invention is to provide an antiviral agent that can improve the symptoms of rhinovirus disease.
상술한 본 발명의 목적은, 메이플시럽, 죽력, 의이인, 자일리톨, 비타민C, 마누카꿀, 유향, 몰약 및 프로폴리스를, 분말, 액상 또는 추출물 형태로 포함하는 항바이러스제에 의하여 달성될 수 있다. The above-described object of the present invention, maple syrup, tabasheer, uiiin, xylitol, vitamin C, manuka honey, frankincense, myrrh and propolis, it can be achieved by an antiviral agent comprising a powder, liquid or extract form.
본 발명에 따른 항바이러스제는, 메이플시럽, 죽력, 의이인, 자일리톨, 비타민C, 유향의 추출물, 몰약, 프로폴리스의 추출물의 혼합분말에, 마누카꿀을 더 혼합하여 환제 또는 과립제로 만들 수 있다. Antiviral agent according to the present invention, maple syrup, tabasheer, uiin, xylitol, vitamin C, extract of frankincense, myrrh, can be made into pills or granules by further mixing manuka honey in the mixed powder of the extract.
본 발명에 따른 항바이러스제는, 메이플시럽, 죽력, 의이인, 자일리톨, 비타민C, 마누카꿀, 유향, 몰약 및 프로폴리스의 혼합물에서 추출한 추출물을 유효성분으로 포함할 수 있다. The antiviral agent according to the present invention may include an extract extracted from a mixture of maple syrup, tabasheer, uiin, xylitol, vitamin C, manuka honey, frankincense, myrrh and propolis as an active ingredient.
본 발명에 따른 항바이러스제는 Rhinovirus 뿐만 아니라, B형 간염, hepatitis C, 대상포진(herpes zoster), adenovirus, 인플루엔자(influenza), avian 인플루엔자(influenza), severe acute respiratory syndrome, novel 인플루엔자(influenza), Middle East respiratory syndrome coronavirus 등 이미 알려진 바이러스성 질환의 증상을 개선하는 효과도 있다. 또한, 본 발명에 따른 항바이러스제는 바이러스성 질환으로 의심되는 다음 질병들의 병증을 개선하거나 치유하는 효과도 있다. The antiviral agent according to the present invention is not only Rhinovirus, but also hepatitis B, hepatitis C, herpes zoster, adenovirus, influenza, avian influenza, severe acute respiratory syndrome, novel influenza, Middle It is also effective in improving symptoms of known viral diseases such as East respiratory syndrome coronavirus. In addition, the antiviral agent according to the present invention has an effect of improving or curing the symptoms of the following diseases suspected as viral diseases.
1) 섬유근육통(fibromyalgia), 만성 근골격 통증, 만성 근막 통증 등과 같이, 동일 부위에 지속적이고 반복적으로 통증이 유발되는 경우는 바이러스에 감염된 것으로 추측된다. 본 발명에 따른 항바이러스제는, 섬유근육통(fibromyalgia), 만성 근골격 통증, 만성 근막 통증 등이 만성화된 경우와 같이, 동일 부위에 지속적이고 반복적으로 통증이 유발되는 병증을 개선하거나 치유하는 효과가 있다.1) If pain is continuously and repeatedly in the same area, such as fibromyalgia, chronic musculoskeletal pain, and chronic myofascial pain, it is presumed to be infected with the virus. The antiviral agent according to the present invention has an effect of improving or curing a condition that continuously and repeatedly causes pain in the same site, such as when fibromyalgia, chronic musculoskeletal pain, chronic myofascial pain, etc. become chronic.
2) 아토피 피부염(atopic dermatitis), allergic rhinitis 등과 같이, 동일 부위에 지속적이고 반복적인 병변이 유발되는 경우는 바이러스에 감염된 것으로 추측된다. 본 발명에 따른 항바이러스제는, 아토피 피부염(atopic dermatitis), allergic rhinitis 등과 같이, 동일 부위에 지속적이고 반복적인 병변이 유발되는 병증을 개선하거나 치유하는 효과가 있다.2) If persistent and repetitive lesions are induced in the same area, such as atopic dermatitis and allergic rhinitis, it is presumed to be infected with the virus. The antiviral agent according to the present invention has an effect of improving or curing a condition in which continuous and repetitive lesions are induced in the same site, such as atopic dermatitis, allergic rhinitis, and the like.
3) 알러지(allergy)나 자가면역질환에 속하는 대부분 질환이 바이러스에 의한 감염증으로 추측된다. 본 발명에 따른 항바이러스제는, 알러지(allergy)나 자가면역질환에 속하는 대부분 질환이나 병증을 개선하거나 치유하는 효과가 있다.3) Most diseases belonging to allergies or autoimmune diseases are presumed to be infections caused by viruses. The antiviral agent according to the present invention has an effect of improving or curing most diseases or conditions belonging to allergies or autoimmune diseases.
4) 건선(psoriasis) 등과 같이, 염증이 있어서 염증부위의 색깔이 약간 붉은 색이 있지만 쉽게 화농 되지 않고 지속적으로 염증이 유지되면서 증상의 경중을 반복하는 경우는 바이러스에 감염된 것으로 추측된다. 본 발명에 따른 항바이러스제는, 염증은 있어서 염증부위의 색깔이 약간 붉은 색이 있지만 쉽게 화농 되지 않고 지속적으로 유지되면서 증상의 경중을 반복하는 병증을 개선하거나 치유하는 효과가 있다. 4) As with psoriasis, if the inflamed area is slightly red in color due to inflammation, but it does not purify easily and the inflammation continues and the severity of symptoms repeats, it is presumed to be infected with a virus. The antiviral agent according to the present invention has an effect of improving or curing a condition that repeats the severity of the symptoms while being continuously maintained without being easily purulent although the color of the inflamed area is slightly red due to inflammation.
5) 점막부위인 눈, 코, 입, 잇몸(치주), 목, 위, 소장, 대장, 방광, 여성생식기 등에 반복적이고 지속적으로 발생하는 chronic inflammation은 바이러스 감염증으로 추측된다. 본 발명에 따른 항바이러스제는, 외부로 노출된 점막부위인 눈, 코, 입, 잇몸(치주), 목, 위, 소장, 대장, 방광, 여성생식기 등에 반복적이고 지속적으로 발생하는 chronic inflammation을 개선하거나 치유하는 효과가 있다.5) Chronic inflammation that occurs repeatedly and continuously in the mucous membranes of the eyes, nose, mouth, gums (periodontal), neck, stomach, small intestine, large intestine, bladder, and female genitalia is presumed to be a viral infection. The antiviral agent according to the present invention improves or improves chronic inflammation that occurs repeatedly and continuously in mucosal sites exposed to the outside such as eyes, nose, mouth, gums (periodontal), neck, stomach, small intestine, large intestine, bladder, female genitalia, etc. It has a healing effect.
6) 당뇨, 고혈압 등과 같은 성인병 또는 life style disease 중 일부는, 관련 부위의 바이러스의 감염이 원인일 것으로 추측된다. 본 발명에 따른 항바이러스제는, 바이러스가 원인이 되어 발병한 당뇨, 고혈압 등과 같은 성인병 또는 life style disease 등의 증상을 개선하거나 치유하는 효과가 있다.6) Some of the adult diseases or lifestyle diseases such as diabetes and high blood pressure are presumed to be caused by virus infection in the relevant area. The antiviral agent according to the present invention has an effect of improving or curing symptoms such as adult diseases or life style diseases, such as diabetes and hypertension, which are caused by viruses.
7) 다운증후군(Down's syndrome), 묘성증후군(Cri du chat syndrome), 근디스트로피(Muscular Dystrophy) 등 유전병이라고 논의되는 질환도 중추신경계의 바이러스성 질환이라고 추측된다. 본 발명에 따른 항바이러스제는, 다운증후군(Down's syndrome), 묘성증후군(Cri du chat syndrome), 근디스트로피(Muscular Dystrophy) 등 유전병이라고 논의되는 질환의 증상을 개선하거나 치유하는 효과가 있다.7) Diseases discussed as genetic diseases such as Down's syndrome, Cri du chat syndrome, and Muscular Dystrophy are also speculated to be viral diseases of the central nervous system. The antiviral agent according to the present invention has an effect of improving or curing symptoms of diseases discussed as genetic diseases, such as Down's syndrome, Cri du chat syndrome, and muscular dystrophy.
8) 발달장애(developmental disorder), 뇌병변장애, 치매(dementia) 등의 중추신경계 질환(central nervous system diseases)의 원인 중 하나도 관련부위의 바이러스에 의한 감염이라고 추측된다. 본 발명에 따른 항바이러스제는, 발달장애(developmental disorder), 뇌병변장애, 치매(dementia) 등의 중추신경계 질환(central nervous system diseases)의 병증을 개선하거나 치유하는 효과가 있다.8) It is assumed that one of the causes of central nervous system diseases such as developmental disorder, brain lesion disorder, and dementia is infection by virus in the relevant area. The antiviral agent according to the present invention is effective in improving or curing conditions of central nervous system diseases such as developmental disorders, brain lesion disorders, and dementia.
본 발명에 따른 항바이러스제는, 메이플시럽, 죽력, 의이인, 자일리톨, 비타민C, 마누카꿀, 유향, 몰약 및 프로폴리스를 분말, 액상 또는 추출물 형태로 포함한다. The antiviral agent according to the present invention includes maple syrup, tabasheer, uiin, xylitol, vitamin C, manuka honey, frankincense, myrrh and propolis in powder, liquid or extract form.
본 발명에 따른 항바이러스제는, 의이인, 자일리톨, 비타민C, 유향의 추출물, 몰약, 프로폴리스의 추출물의 혼합분말에, 마누카꿀, 메이플시럽 및 죽력을 더 혼합하여 환제 또는 과립제로 만들 수 있다.The antiviral agent according to the present invention can be made into pills or granules by further mixing manuka honey, maple syrup and tabasheer in the mixed powder of uiin, xylitol, vitamin C, frankincense extract, myrrh, and propolis extract.
본 발명에 따른 항바이러스제는, 메이플시럽, 죽력, 의이인, 자일리톨, 비타민C, 마누카꿀, 유향, 몰약 및 프로폴리스의 혼합물에서 추출한 추출물을 유효성분으로 포함할 수 있다.The antiviral agent according to the present invention may include an extract extracted from a mixture of maple syrup, tabasheer, uiin, xylitol, vitamin C, manuka honey, frankincense, myrrh and propolis as an active ingredient.
본 발명의 조성성분 및 성분간 조성비율은 다음과 같다.The compositional components of the present invention and the composition ratio between the components are as follows.
1)캐나다 단풍나무의 수액을 모아서 농축한 메이플시럽 1~30중량%;1) 1 to 30% by weight of concentrated maple syrup by collecting the sap of Canadian maple;
2)대나무로 숯을 만드는 과정에서 강한 열에 의해 증발되는 대나무의 수액인 죽력(천연죽향) 1~30중량%;2) 1 to 30% by weight of bamboo sap, bamboo sap (natural bamboo flavor), evaporated by strong heat in the process of making charcoal from bamboo;
3)항균기능이 있는 것으로 알려진 식품재료인 의이인 5~60중량%(전체중량기준, 이하 같음);3) 5 to 60% by weight of Uiyin, a food ingredient known to have antibacterial properties (based on total weight, the same as below);
4) 역시 항균기능이 있는 것으로 알려진 식품재료인 자일리톨 10~40중량%;4) 10-40% by weight of xylitol, a food ingredient also known to have antibacterial properties;
5) 항산화물질로 알려진 영양제인 비타민C 1~20중량%;5) 1 to 20% by weight of vitamin C, a nutritional supplement known as an antioxidant;
6) 항박테리아 활성 물질을 갖는 것으로 알려진 식품인 마누카꿀 1~20중량%;6) 1-20% by weight of Manuka honey, a food known to have antibacterial active substances;
7) 해독소종기능이 있는 것으로 알려진 식품인 유향 1~20중량%;7) 1 to 20% by weight of frankincense, a food known to have detoxifying properties;
8) 어혈 제거 기능이 있는 것으로 알려진 식품인 몰약 1~20중량%;8) 1 to 20% by weight of myrrh, a food known to have the function of removing eohyeol;
9) 벌통에서 추출한 것으로 식품재료로도 사용되는 프로폴리스 0.1~10중량%.9) 0.1~10% by weight of propolis extracted from the beehive and used as a food ingredient.
의이인을 5중량%미만으로 첨가하면 의이인에 의한 항바이러스 효과가 미미하고, 의이인을 60중량%를 초과하여 첨가하면 의이인에 의한 항바러스 효과 증대는 적은 반면, 다른 재료에 의한 항바이러스 기능을 추가하기 어려워 다양한 종류의 바이러스에 대하여 효능을 갖게 하기 어렵다.When the uiiin is added in less than 5% by weight, the antiviral effect by the uiiin is insignificant, and when the uiiin is added in excess of 60% by weight, the increase in the antiviral effect by the uiiin is small, while adding the antiviral function by other materials It is difficult to make it effective against various types of viruses.
메이플시럽을 1중량%미만으로 첨가하면 메이플시럽에 의한 항바이러스 효과가 미미하고, 메이플시럽을 30중량%를 초과하여 첨가하면 메이플시럽에 의한 항바러스 효과 증대는 적은 반면, 다른 재료에 의한 항바이러스 기능을 추가하기 어려워 다양한 종류의 바이러스에 대하여 효능을 갖게 하기 어렵다.When maple syrup is added in less than 1% by weight, the antiviral effect by maple syrup is insignificant, and when maple syrup is added in excess of 30% by weight, the increase in the antiviral effect by maple syrup is small, whereas the antiviral effect caused by other materials is small. Since it is difficult to add a function, it is difficult to have efficacy against various types of viruses.
죽력을 1중량%미만으로 첨가하면 죽력에 의한 항바이러스 효과가 미미하고, 죽력을 30중량%를 초과하여 첨가하면 죽력에 의한 항바러스 효과 증대는 적은 반면, 다른 재료에 의한 항바이러스 기능을 추가하기 어려워 다양한 종류의 바이러스에 대하여 효능을 갖게 하기 어렵다. When the tabasheer is added to less than 1% by weight, the antiviral effect by tabasheer is insignificant, and when the tabasheer is added in excess of 30% by weight, the increase in the antiviral effect by tabasheer is small, while adding the antiviral function by other materials It is difficult to make it effective against various types of viruses.
자일리톨을 10중량% 미만으로 첨가하면 자일리톨에 의한 항바이러스 효과가 미미하고, 자일리톨을 40중량%를 초과하여 첨가하면 자일리톨에 의한 항바러스 효과 증대는 적은 반면, 다른 재료에 의한 항바이러스 기능을 추가하기 어려워 다양한 종류의 바이러스에 대하여 효능을 갖게 하기 어렵다. When xylitol is added in an amount of less than 10% by weight, the antiviral effect by xylitol is insignificant, and when xylitol is added in excess of 40% by weight, the increase in the antiviral effect by xylitol is small, while adding antiviral function by other materials It is difficult to make it effective against various types of viruses.
비타민C를 1중량% 미만으로 첨가하면 비타민C에 의한 항바이러스 효과가 미미하고, 비타민C를 20중량%를 초과하여 첨가하면 비타민C에 의한 항바러스 효과 증대는 적은 반면, 다른 재료에 의한 항바이러스 기능을 추가하기 어려워 다양한 종류의 바이러스에 대하여 효능을 갖게 하기 어렵다. When vitamin C is added in an amount of less than 1% by weight, the antiviral effect by vitamin C is insignificant, and when vitamin C is added in excess of 20% by weight, the increase in the antiviral effect by vitamin C is small, whereas the antiviral effect caused by other materials is small. Since it is difficult to add a function, it is difficult to have efficacy against various types of viruses.
마누카꿀을 1중량% 미만으로 첨가하면 마누카꿀에 의한 항바이러스 효과가 미미하고, 마누카꿀을 20중량%를 초과하여 첨가하면 마누카꿀에 의한 항바러스 효과 증대는 적은 반면, 다른 재료에 의한 항바이러스 기능을 추가하기 어려워 다양한 종류의 바이러스에 대하여 효능을 갖게 하기 어렵다. When Manuka honey is added in an amount of less than 1% by weight, the antiviral effect by Manuka honey is insignificant, and when Manuka honey is added in excess of 20% by weight, the increase in the antiviral effect by Manuka honey is small, whereas the antiviral effect caused by other materials is small. Since it is difficult to add a function, it is difficult to have efficacy against various types of viruses.
유향을 1중량% 미만으로 첨가하면 유향에 의한 항바이러스 효과가 미미하고, 유향을 20중량%를 초과하여 첨가하면 유향에 의한 항바러스 효과 증대는 적은 반면, 다른 재료에 의한 항바이러스 기능을 추가하기 어려워 다양한 종류의 바이러스에 대하여 효능을 갖게 하기 어렵다. When frankincense is added in an amount of less than 1% by weight, the antiviral effect of frankincense is insignificant, and when frankincense is added in excess of 20% by weight, the increase in the antiviral effect of frankincense is small, while adding the antiviral function by other materials. It is difficult to make it effective against various types of viruses.
몰약를 1중량% 미만으로 첨가하면 몰약에 의한 항바이러스 효과가 미미하고, 몰약를 20중량%를 초과하여 첨가하면 몰약에 의한 항바러스 효과 증대는 적은 반면, 다른 재료에 의한 항바이러스 기능을 추가하기 어려워 다양한 종류의 바이러스에 대하여 효능을 갖게 하기 어렵다. When the amount of myrrh is added less than 1% by weight, the antiviral effect of myrrh is insignificant, and when the amount of myrrh exceeds 20% by weight, the increase in the antiviral effect of myrrh is small, while it is difficult to add the antiviral function by other materials. It is difficult to make it effective against a kind of virus.
프로폴리스를 0.1중량% 미만으로 첨가하면 프로폴리스의 항바이러스 효과가 미미하고, 프로폴리스를 10중량%를 초과하여 첨가하면 프로폴리스에 의한 항바러스 효과 증대는 적은 반면, 다른 재료에 의한 항바이러스 기능을 추가하기 어려워 다양한 종류의 바이러스에 대하여 효능을 갖게 하기 어렵다.When propolis is added in an amount of less than 0.1% by weight, the antiviral effect of propolis is insignificant, and when propolis is added in excess of 10% by weight, the increase in the antiviral effect by propolis is small, while the antiviral function by other materials Since it is difficult to add , it is difficult to have efficacy against various types of viruses.
본 발명에 따른 항바이러스제는, 메이플시럽, 죽력, 의이인, 자일리톨, 비타민C, 유향, 몰약의 혼합분말에, 마누카꿀과 프로폴리스를 더 혼합하여 내복용 환제, 과립제, 또는 분말로 만들 수 있다. Antiviral agent according to the present invention, maple syrup, tabasheer, uiin, xylitol, vitamin C, frankincense, and myrrh mixed powder, Manuka honey and propolis can be further mixed to make pills, granules, or powder for oral use.
본 발명에 따른 항바이러스제는, 메이플시럽, 죽력, 의이인, 자일리톨, 비타민C, 유향의 추출물, 몰약, 프로폴리스의 추출물의 혼합분말에, 마누카꿀을 더 혼합하여 내복용 환제, 과립제, 또는 분말로 만들 수 있다. The antiviral agent according to the present invention is a mixture of maple syrup, tabasheer, uiin, xylitol, vitamin C, frankincense extract, myrrh, and propolis extract, and Manuka honey is further mixed to form pills, granules, or powders for oral use. can make
본 발명에 따른 항바이러스제는, 메이플시럽, 죽력, 의이인, 자일리톨, 비타민C, 마누카꿀, 유향, 몰약 및 프로폴리스를 혼합하여 물, 또는 에탄올, 또는 물과 에탄올로 추출한 추출물을 유효성분으로 포함하는 내복용 환제, 과립제, 분말, 또는 액상로 만들 수 있다. Antiviral agent according to the present invention, maple syrup, tabasheer, uiin, xylitol, vitamin C, manuka honey, frankincense, myrrh and propolis mixed with water, or ethanol, or an extract extracted with water and ethanol as an active ingredient It can be made into pills, granules, powders, or liquids for oral use.
메이플 시럽은, 캐나다 단풍나무의 수액을 모아서 농축한 것으로 현재 설탕의 대용품으로 많이 활용되고 있는 것이다.Maple syrup, which is concentrated by collecting the sap of Canadian maple trees, is currently being used as a substitute for sugar.
죽력(천연죽향)은, 대나무로 숯을 만드는 과정에서 강한 열에 의해 증발되는 대나무의 수액을 모은 것 맛은 달고 성질은 차다. 한의학에서 심경(心經), 위경(胃經)에 작용하고, 열을 내리고 가래를 삭인다고 알려져 있다. Bamboo power (natural bamboo flavor), It is a collection of bamboo sap that is evaporated by strong heat in the process of making charcoal from bamboo. The taste is sweet and the nature is cold. In oriental medicine, it is known that it works on the heart and stomach and relieves heat and phlegm.
의이인은 벼과 식물(gramineae species)인 율무의 여문 씨를 말린 것이다. 율무는 한국의 각지에서 심는다. Ui-in is the dried seed of Yulmu, a gramineae species. Yulmu is planted in various parts of Korea.
자일리톨은 자작나무 껍질과 수액으로부터 추출한 5탄당(C5H12O5. 분자량 152.15)이다. Xylitol is a pentose (C 5 H 12 O 5 . molecular weight 152.15) extracted from birch bark and sap.
비타민C는 항산화 물질로 신체를 활성산소로부터 보호하여 암, 동맥경화, 류머티즘 등을 예방해 주며, 면역 체계도 강화시킨다. Vitamin C is an antioxidant that protects the body from free radicals to prevent cancer, arteriosclerosis, rheumatism, and strengthens the immune system.
마누카 꿀은 뉴질랜드가 원산지인 마누카 나무의 꽃이 생산한 꿀을 꿀벌에 의하여 벌통에 모은 것이다. Manuka honey is honey produced by the flowers of the Manuka tree, which is native to New Zealand, and collected by bees in a hive.
유향은, 감람과(橄欖科)(Burseraceae)에 속한 열대식물인 유향수(乳香樹)의 수간(樹幹) 및 수피(樹皮)에서 삼출(渗出)하는 수지를 응결건조한 것이다. Frankincense is a condensed-dried resin exuding from the trunk and bark of frankincense, a tropical plant belonging to the olive family (Bursaceae).
몰약은, 감람과(Burseraceae)에 소한 소교목(小喬木)인 몰약(미르라)의 수간(樹幹), 피부(皮部)의 상구(傷口)로부터 삼출(渗出)하는 황즙(黃汁)의 유상수지(乳狀樹脂)가 건조되어 적갈색의 괴상(塊狀)을 이룬 것이다. Myrrh is derived from the stem of myrrh (myrra), a small tree in the family Burseraceae, and yellow juice exuding from the upper mouth of the skin. The oily resin (乳狀樹脂) is dried to form a reddish-brown mass.
프로폴리스는 꿀벌이 나무, 풀, 꽃에서 나오는 수지를 수집하여 자신의 침과 분비물 등을 섞어 만든 것이다. Propolis is made by honey bees collecting resin from trees, grass, and flowers and mixing their saliva and secretions.
본 발명에 따른 항바이러스제의 구성 성분 중 메이플시럽, 죽력, 의이인, 자일리톨, 마누카꿀, 유향, 몰약 및 프로폴리스는 자연의 생명체에서 유래한 것들이고, 이들의 개별적인 항바이러스 효과는 미미하나, 이들이 결합될 경우, 다양한 바이러스 질환에 대해, 개별적인 효과로부터 예기치 못할, 큰 상승 효과를 나타낸다. Among the components of the antiviral agent according to the present invention, maple syrup, tabasheer, uiiin, xylitol, manuka honey, frankincense, myrrh and propolis are those derived from living things in nature, and their individual antiviral effects are insignificant, but they can be combined. In this case, it shows a large synergistic effect, unexpected from the individual effects, for various viral diseases.
바이러스성 질환의 특징 중 하나는, 피부와 점막처럼 외부 물질과의 접촉이 빈번한 부위에 집중적으로 발생한다는 것이다. 대부분의 바이러스는 접촉에 의해 감염이 되므로 외부 물질이나 물체와 접촉이 빈번한 피부나 점막 부위에 많이 감염된다. 바이러스는 건강한 피부로 직접 침투하기 어려워서, 모낭충(acarus folliculorum)의 감염이 있는 부위, 염증이 발생한 부위 또는 피부손상이 있는 부위를 통해 감염되기 쉽다. 바이러스는 점막 어디나 침투가 용이하여, 코 내벽, 기관지 내벽, 입안 내벽, 위벽, 소장의 내벽, 대장의 내벽, 항문의 내벽, 질의 내벽, 자궁의 내벽, 눈의 각막 및 결막 등에 감염될 수 있다. 특정 세포를 선호하는 바이러스는 특정한 부위에만 감염되기도 한다. B형 간염 바이러스처럼 특정 세포에 친화적인 바이러스인 경우에는 특정한 부위에만 감염된다. One of the characteristics of viral diseases is that they occur intensively in areas where contact with external substances is frequent, such as the skin and mucous membranes. Since most viruses are transmitted by contact, they are often infected on the skin or mucous membranes where contact with foreign substances or objects is frequent. Since the virus is difficult to penetrate directly into healthy skin, it is easy to infect through areas with an infection of acarus folliculorum, areas with inflammation, or areas with skin damage. The virus easily penetrates into any mucous membrane, so it can infect the nasal lining, bronchial lining, mouth lining, stomach lining, small intestine lining, large intestine lining, anus lining, vaginal lining, uterine lining, eye cornea and conjunctiva, etc. Viruses that prefer specific cells may infect only a specific site. In the case of a virus that is friendly to a specific cell, such as hepatitis B virus, it infects only a specific site.
바이러스성 질환의 다른 특징은, 증상이 깨끗하게 낫지 않고 건강상태에 따라 증상이 반복된다는 것이다. 면역력이 정상이면 세포 안에서만 생존하여 특별한 병변을 일으키지 않는다. 그러다가 면역력이 약해지면 주변세포를 전염시키고 고유의 병변을 일으킨다. 이렇듯 바이러스 질환은 증상이 깨끗이 낫지 않고 면역력에 따라 반복되고 지속 된다. Another characteristic of viral diseases is that the symptoms do not get better and the symptoms repeat depending on the state of health. If immunity is normal, it survives only in cells and does not cause special lesions. Then, when immunity is weakened, it infects surrounding cells and causes unique lesions. As such, the symptoms of viral diseases do not get better and repeat and persist depending on the immune system.
바이러스성 질환의 또 다른 특징으로는, 원인이 되는 바이러스를 찾기가 어렵다는 것이다. 세균성 질환은 원인균을 찾기가 쉽다. 하지만 병원성이 약하면서 만성질환을 일으키는 바이러스성 질환인 경우에는 평소에는 세포 안에 숨어있어 염증을 일으키지 않다가, 면역력이 떨어지면 미약하게 염증을 유발하거나 세포의 반응성을 민감하게 한다. 특정 질환의 원인 바이러스는 면역력이 약한 환자의 동일 부위에서 지속적으로 발견될 수 있다. 따라서, 해당 바이러스를 특정 질환의 원인 바이러스로 판단할 수 있다. 그러나, 해당 바이러스는 특정 질환의 발병 경험이 전혀 없는 면역력이 강한 정상인의 비슷한 부위에서도 발견될 수 있다. 그 결과, 해당 바이러스를 특정 질환의 원인 바이러스로 결론짓지 못하고 병원성이 없는 바이러스로 분류할 수 있다. 한편, 위와 같은 특징을 갖는 질환을 바이러스성 질환으로 추측하고, 본 발명에 따른 항바이러스제를 적용하면, 증상이 개선되거나 치유되는 것을 확인할 수 있었다. Another characteristic of viral diseases is that it is difficult to find the causative virus. Bacterial diseases are easy to find the causative organism. However, in the case of a viral disease that causes chronic disease with weak pathogenicity, it usually hides in cells and does not cause inflammation. Viruses that cause specific diseases can be continuously found in the same area of patients with weakened immunity. Accordingly, the corresponding virus may be determined as the causative virus of a specific disease. However, the virus can also be found in a similar area of a normal person with strong immunity who has no experience of developing a specific disease. As a result, the virus cannot be concluded as the causative virus of a specific disease and can be classified as a non-pathogenic virus. On the other hand, when a disease having the above characteristics is assumed to be a viral disease, and the antiviral agent according to the present invention is applied, it was confirmed that the symptoms were improved or cured.
이미 알려진 바이러스성 질환으로는, 인플루엔자(influenza), 바이러스성 간염(viral hepatitis), 바이러스성 장염(viral enteritis), 대상포진(herpes zoster), 바이러스 결막염(viral conjunctivitis), 소아마비(infantile paralysis), AIDS, 바이러스성 뇌병변장애, 홍역(measles), 유행성이하선염(mumps)등이 있다. 이러한 바이러스성 질환들에 있어서도, 아직까지 제대로 된 항바이러스제가 개발되지 못하고 있는 경우도 많다. Known viral diseases include influenza, viral hepatitis, viral enteritis, herpes zoster, viral conjunctivitis, polio, and AIDS. , viral encephalopathy, measles, mumps, etc. Even in these viral diseases, there are many cases where a proper antiviral agent has not yet been developed.
위에 설명한 바이러스 질환의 특징을 모두 갖는 질환으로는 다음의 것들이 있다.Diseases that have all the characteristics of the viral diseases described above include the following.
백반증 등의 자가면역질환; 아토피 피부염 등의 알러지(allergy)성 질환; 근골격의 만성 통증 질환; 유소아의 병약 또는 발육부진; 고혈압 및 당뇨 등의 생활습관질환; 일부 불임; 발달장애(developmental disorder), 뇌병변장애 등의 중추신경계 질환(central nervous system diseases); 다운증후군(Down's syndrome), 묘성증후군(Cri du chat syndrome), 근디스트로피(Muscular Dystrophy) 등과 같이 유전질환으로 알려진 질환; 치매(dementia).autoimmune diseases such as vitiligo; allergic diseases such as atopic dermatitis; chronic pain disorders of the musculoskeletal system; sickness or stunting in infants and children; lifestyle diseases such as high blood pressure and diabetes; some infertility; developmental disorders, central nervous system diseases, such as brain lesion disorders; Diseases known as genetic disorders, such as Down's syndrome, Cri du chat syndrome, and Muscular Dystrophy; Dementia.
이들 질환은 모두 바이러스성 질환이거나, 바이러스 감염과 연관된 질환일 것으로 추측된다. All of these diseases are either viral diseases or diseases associated with viral infections.
자가면역질환은, 정확히 병의 원인은 모르지만 몸 안에 있는 어떤 물질에 의해 면역세포가 반응하여 지속적으로 염증반응이 나타나는 질환으로, 백반증, 류머티즘, 크론병(Crohn's disease), 루푸스(lupus), 천포창(pemphigus) 등이다. 이들 질환은 우리 몸에서 면역반응이 일어나서 지속적으로 염증이 생기고 있는 상태를 의미하는 데, 세균이나 진균은 발견되지 않아서 염증의 원인을 찾을 수 없기 때문에 자가면역질환이라고 이름 붙여진 것이다. 자가면역질환은 위에서 설명한 바이러스성 질환의 전형적인 특징을 모두 나타내는 질환이다. 본원 발명자는, 자가면역질환을, 몸 안에 있는 어떤 물질에 의해 면역반응이 일어나서 염증이 생기는 질환이 아니라 바이러스 감염으로 인해 감염 부위에 면역반응이 일어나서 염증이 생기는 바이러스 감염질환이라고 추측한다. Autoimmune disease is a disease in which the exact cause of the disease is unknown, but the immune cells react to certain substances in the body and the inflammatory reaction continuously appears. Vitiligo, rheumatism, Crohn's disease, lupus, pemphigus ( pemphigus), etc. These diseases refer to a condition in which inflammation is continuously occurring due to an immune response in our body, and since bacteria or fungi are not found and the cause of inflammation cannot be found, they are named autoimmune diseases. Autoimmune diseases are diseases that show all the typical characteristics of the viral diseases described above. The inventors of the present invention speculate that autoimmune disease is not a disease in which an immune response is caused by a certain substance in the body and causes inflammation, but is a viral infection disease in which an immune response occurs at an infected site and inflammation occurs due to a viral infection.
알러지(allergy)와 자가면역질환은 면역 과잉반응이라는 관점에서 보면 같은 질환이고, 장기 특이적인 자가면역질환의 대부분이 제Ⅱ형 알러지(allergy)에 포함되어 있는 것으로 경계선을 찾기가 어렵다. 구분하면 알러지(allergy) 항원의 실체가 명확하게 밝혀진 것이 알러지(allergy)이고, 아직 밝혀지지 않은 것이 자가면역질환이다. 하지만 본원 발명자는, 아토피를 비롯한 대부분의 알러지(allergy)를, 비교적 병원성이 약한 바이러스가 세포 안에 들어가 세포의 상태를 예민하게 하고 여기에 또 다른 염증물질인 항원이 세포를 자극하여 면역반응을 유발하는 바이러스성 질환으로 추측한다. Allergy and autoimmune disease are the same disease from the point of view of immune overreaction, and it is difficult to find a boundary as most organ-specific autoimmune diseases are included in type II allergy. To be distinguished, allergy (allergy) is one in which the substance of the antigen has been clearly identified, and one that has not yet been identified is autoimmune disease. However, the inventor of the present invention, for most allergies including atopy, a relatively weak virus enters the cell and makes the state of the cell sensitive, and another inflammatory substance, an antigen, stimulates the cell to induce an immune response. It is assumed to be a viral disease.
섬유근육통(fibromyalgia), 만성 근골격 통증 등과 같이, 근육이나 인대가 손상되었을 경우 면역력이 떨어지고 손상된 세포가 완전하게 회복되기 전에 바이러스에 감염되면 증상이 악화 된다. 또 바이러스성 염증의 특성상 염증이 깨끗하게 낫지 않고 지속적으로 증상이 반복되면서 진행된다. 이런 경우 본 발명에 따른 항바이러스제에 의한 바이러스의 퇴치와 환부의 적절한 강화운동으로 확실하게 증상이 개선되는 것을 많은 임상을 통하여 확인하였다. 또 외부 충격이나 무리한 운동으로 근육이나 인대가 손상되어 깨끗하게 낫지 않고 반복적이고 지속적인 증상을 유발하는 경우에도 바이러스 감염증에 해당하는 것을 임상을 통하여 확인하였다.As with fibromyalgia and chronic musculoskeletal pain, when muscles or ligaments are damaged, immunity is weakened, and symptoms worsen if infected with a virus before damaged cells are fully recovered. In addition, due to the nature of viral inflammation, the inflammation does not heal cleanly and the symptoms continue to repeat. In this case, it has been confirmed through many clinical trials that the symptoms are surely improved with the antiviral agent according to the present invention and appropriate strengthening exercise for the affected area. In addition, it was confirmed through clinical practice that even if the muscle or ligament was damaged by an external shock or excessive exercise, which did not heal cleanly and caused repeated and continuous symptoms, it was a viral infection.
본원 발명자는, 유소아의 특이적 병약 또는 발육부진도 바이러스성 질환으로 추측한다. 어린 아이의 바이러스 감염은 반복적인 감기 증상, 편도선비대, 성장부진, 체력저하, 식욕부진, 소화기능의 약화 등의 여러 가지 증상을 유발하여 성장발육을 방해할 수 있다. 이런 경우 바이러스의 퇴치는 병약한 아이를 건강하게 하여 정상적인 성장발육을 돕는다.The inventors of the present invention speculate that the specific illness or stunting in infants and children is also a viral disease. Viral infection in young children can impede growth and development by causing various symptoms such as repeated cold symptoms, enlarged tonsils, poor growth, decreased physical strength, loss of appetite, and weakened digestive function. In this case, the eradication of the virus helps the sick child to grow and develop normally.
본원 발명자는, 고혈압과 diabetes도 바이러스와 연관된 질환일 것으로 추측한다. 1형 당뇨의 원인은 볼거리나 풍진 등의 바이러스 감염 후 생긴 항체가 췌장을 파괴하는 것으로 알려져 있다. 하지만 1형 당뇨환자의 임상 사례에서 본 발명에 따른 항바이러스제가 핵심으로 작용하여 인슐린을 줄인 예를 다수 확인했다. 또 조절이 잘 안 되는 제2형 당뇨환자나 고혈압환자 중에서 본 발명에 따른 항바이러스제 복용만으로도 어느 정도 안정되어 관리가 되는 임상 사례를 자주 경험하면서 당뇨병이나 고혈압환자 중에는 바이러스가 직접적인 원인이거나 2차적으로 증상을 악화시키는 원인으로 작용하는 경우가 많을 것으로 추측하게 되었다.The inventors of the present invention speculate that hypertension and diabetes are also virus-related diseases. It is known that the cause of type 1 diabetes is that antibodies generated after viral infection such as mumps or rubella destroy the pancreas. However, in clinical cases of type 1 diabetic patients, a number of examples in which the antiviral agent according to the present invention acted as a key and reduced insulin were confirmed. In addition, among patients with poorly controlled type 2 diabetes or hypertension, clinical cases in which the antiviral agent according to the present invention is stable and managed to a certain extent are frequently experienced. It was speculated that there are many cases that act as a cause of exacerbation.
본원 발명자는, 불임도 바이러스와 연관된 질환일 것으로 추측한다. 앞에서 언급한 것처럼 점막은 바이러스 감염이 되기 쉬운 부위로 생식기 점막에 바이러스 감염이 수시로 일어날 수 있고 이러한 감염으로 염증이 심해지면 불임을 유발할 수 있다. 따라서 불임여성의 경우에도 본 발명에 따른 항바이러스제를 복용하면서 바이러스를 박멸하는 것이 필요하다. 바이러스가 없어지는 것만으로도 체력이 좋아지고 임신이 잘 되는 경우를 임상 사례를 통하여 여러 번 확인하였다. The inventors of the present invention speculate that infertility is also a disease associated with the virus. As mentioned earlier, the mucous membrane is a site prone to viral infection, and viral infections may occur frequently in the genital mucosa, and if the infection becomes severe, infertility may occur. Therefore, even in the case of infertile women, it is necessary to eradicate the virus while taking the antiviral agent according to the present invention. Through clinical cases, cases in which physical strength improves and pregnancy is successful just by eliminating the virus have been confirmed several times.
본원 발명자는 발달장애(developmental disorder), 뇌병변장애 등의 중추신경계 질환도 바이러스와 연관된 질환일 것으로 추측한다. 발달장애(developmental disorder)는 본원 발명자가 여러 임상 사례를 통하여 바이러스성 중추신경계 질환으로 추측한 질환이고 지금도 바이러스성 중추신경계 질환으로 추측되는 임상 사례가 끊이지 않고 나오는 질환이다. 아직까지 현대의학에서 밝혀지지 않았지만 발달장애(developmental disorder), 뇌병변장애 등의 질환을 바이러스에 의한 중추신경계 질환으로 추측하고 본 발명에 따른 항바이러스제 복용을 기본으로 하는 신경재생과정으로 개선되는 경우를 여러 번 경험하게 되었다. 또 바이러스가 박멸되면서 지능이 높아지고 증상이 개선되는 것을 수시로 확인하였다.The inventors of the present invention speculate that central nervous system diseases such as developmental disorders and brain lesion disorders are also virus-related diseases. Developmental disorder (developmental disorder) is a disease that the inventors of the present invention guessed as a viral central nervous system disease through several clinical cases, and is a disease that continues to appear in clinical cases presumed to be a viral central nervous system disease. Although it has not yet been identified in modern medicine, it is assumed that diseases such as developmental disorders and brain lesion disorders are central nervous system diseases caused by viruses and are improved by the nerve regeneration process based on taking the antiviral agent according to the present invention. experienced several times. In addition, as the virus was eradicated, it was often confirmed that intelligence increased and symptoms improved.
본원 발명자는 다운증후군(Down's syndrome), 묘성증후군(Cri du chat syndrome), 근디스트로피(Muscular Dystrophy) 등 현대의학에서 유전 질환으로 보는 질병들도 바이러스와 연관된 질환일 것으로 추측한다. 다운증후군(Down's syndrome), 묘성증후군(Cri du chat syndrome), 근디스트로피(Muscular Dystrophy) 등과 같은 원인불명이거나 유전질환으로 논의되는 많은 신경성 질환들이 본 발명에 따른 항바이러스제의 복용을 기본으로 하는 신경재생과정으로 개선되는 경우를 여러 번 경험하게 되었다. 이러한 반복된 경험을 통해서 유전병으로 논의되는 질환 중에도 바이러스 감염으로 인한 질환이 많을 것으로 추측하게 되었다.The inventors of the present invention speculate that diseases such as Down's syndrome, Cri du chat syndrome, and muscular dystrophy (Muscular Dystrophy), which are viewed as genetic diseases in modern medicine, are also virus-related diseases. Many neurological diseases of unknown cause or discussed as genetic diseases, such as Down's syndrome, Cri du chat syndrome, and muscular dystrophy, are nerve regeneration based on the administration of the antiviral agent according to the present invention. I have experienced many cases of improvement through the process. Through these repeated experiences, it was speculated that there are many diseases caused by viral infection among the diseases discussed as genetic diseases.
본원 발명자는 치매(dementia)도 바이러스와 연관된 질환일 것으로 추측한다. 발달장애(developmental disorder), 뇌병변장애 등의 원인을 바이러스에 의한 중추신경계 질환로 추측하고 바이러스를 박멸할 때 증상이 개선되는 것으로 보아 치매(dementia)도 같은 원인으로 추측하게 된 것이다. 치매(dementia)의 예방과 치료에도 본 발명에 따른 항바이러스제는 큰 역할을 할 것으로 생각한다. The present inventors speculate that dementia is also a virus-related disease. As the cause of developmental disorder and brain lesion disorder was assumed to be a central nervous system disease caused by a virus, and the symptoms improved when the virus was eradicated, dementia was assumed to be the same cause. It is thought that the antiviral agent according to the present invention will also play a large role in the prevention and treatment of dementia.
이와 같이, 지금까지의 연구와 임상경험을 바탕으로, 원인이 아직 밝혀지지 않은 많은 질병과 유전병으로 생각되는 많은 질환이 바이러스성 질환에 속할 것이라고 추측한다. As such, based on the research and clinical experience so far, it is speculated that many diseases with unknown causes and many diseases thought to be genetic diseases will belong to viral diseases.
[실시 예][Example]
1) 바이러스 질환에 대한 in-vitro 시험을 위하여 본 발명에 따른 항바이러스제 추출물을 다음과 같은 양으로 수차례 제조하였다. 1) For an in-vitro test for viral diseases, the antiviral extract according to the present invention was prepared several times in the following amount.
메이플시럽 180g, 죽력 220g, 의이인분말 320g, 마누카꿀 120g, 자일리톨분말 270g, 비타민C분말 120g, 보스웰리아 50g, 몰약분말 100g, 프로폴리스 20g의 혼합물을 50% 에탄올과 1:30(혼합물 1 : 50% 에탄올 30)의 중량 비율로 섞어서 압력추출기에서 100~120℃ 온도로 3~12시간 동안 추출하여 항바이러스제 추출물을 만들었다.180g of maple syrup, 220g of tabasheer, 320g of Euiin powder, 120g of Manuka honey, 270g of xylitol powder, 120g of vitamin C powder, 50g of boswellia, 100g of myrrh powder, 20g of propolis is mixed with 50% ethanol 1:30 (Mixture 1: 50% ethanol 30) was mixed in a weight ratio and extracted for 3 to 12 hours at a temperature of 100 to 120 ° C in a pressure extractor to make an antiviral extract.
2) 바이러스성 질환에 대한 임상 실험 및 약효 확인을 위하여 본 발명에 따른 항바이러스제 환을 다음과 같은 비율로 수차례 제조하였다. 2) Antiviral drug pills according to the present invention were prepared several times at the following ratios for clinical trials and drug efficacy confirmation for viral diseases.
메이플시럽 10%, 죽력 12%, 의이인 분말 20중량%, 자일리톨 분말 22중량%, 비타민C 분말 7중량%, 유향의 추출물 분말 5중량%, 몰약 분말 10중량%, 프로폴리스의 추출물 분말 2중량%의 혼합분말을 만들고, 여기에 마누카꿀 12중량%를 더 혼합하여 직경 3.8mm의 작은 동결건조 환으로 만든 후, 4.8g 단위로 포장하였다. 유향의 추출물과 프로폴리스의 추출물을 얻기 위해, 유향 및 프로폴리스를 각각 50% 에탄올과 1:30(유향 또는 프로폴리스 1 : 50% 에탄올 30)의 중량 비율로 섞어서 압력추출기에서 100~120℃ 온도로 3~12시간 동안 추출하고, 이후 에탄올의 성분을 제거하기 위하여 적정 시간 동안 에탄올을 증발시키고 찌꺼기를 제거한 후 건조시켜 분말화하였다.Maple syrup 10%, tabasheer 12%, uiiin powder 20% by weight, xylitol powder 22% by weight, vitamin C powder 7% by weight, frankincense extract powder 5% by weight, myrrh powder 10% by weight, propolis extract powder 2% by weight After making a mixed powder of, 12% by weight of Manuka honey was further mixed thereto to make a small freeze-dried pill having a diameter of 3.8mm, and then packaged in units of 4.8g. In order to obtain an extract of frankincense and propolis, frankincense and propolis are mixed with 50% ethanol and 1:30 (balm or propolis 1:50% ethanol 30) in a weight ratio, respectively, and the temperature is 100~120℃ in a pressure extractor. After extraction for 3 to 12 hours, the ethanol was evaporated for an appropriate time to remove the ethanol component, the residue was removed, and the mixture was dried and powdered.
<항바이러스 시험><Antiviral test>
Influenza A virus(H1N1: A형 독감 바이러스), Human Rhinovirus(HRV:코감기 바이러스), Transmissible gastroenteritis virus(TGEV:전염성위장염 바이러스) 및 Encephalomyocarditis virus(EMCV:뇌심근염 바이러스)를 시험 바이러스로 사용하여, 본 발명에 따른 항바이러스제의 항바이러스능을 측정하는 시험을 ASTM E1052-11에 따라 실시 하였다. Influenza A virus (H1N1: influenza A virus), Human Rhinovirus (HRV: nasal flu virus), Transmissible gastroenteritis virus (TGEV: Infectious gastroenteritis virus) and Encephalomyocarditis virus (EMCV: encephalomyocarditis virus) were used as test viruses. A test for measuring the antiviral activity of the antiviral agent according to the invention was conducted according to ASTM E1052-11.
1.1. 숙주세포의 배양1.1. Host cell culture
MDCK, HeLa, ST, Vero세포를 세포배양배지를 이용하여 5% CO2 농도, (36±2)℃조건으로 배양하였다.MDCK, HeLa, ST, and Vero cells were cultured using a cell culture medium at 5% CO 2 concentration, (36±2)°C conditions.
1.2. 바이러스의 배양1.2. virus culture
1.2.1. Influenza A 배양1.2.1. Influenza A culture
75-cm²flask에 단층배양한 MDCK 세포를 PBS로 세척 후, Influenza A 희석액 3mL를 접종하였다. 5% CO2 농도, (33±2)℃조건으로 60~90분간 바이러스를 감염시킨 후, 바이러스배양배지를 첨가하여 90% 이상의 숙주세포가 세포병변을 보일 때까지 바이러스를 (5~7)일간 배양하였다. 그 후 배양 상층액을 2000rpm에서 10분간 원심분리하고 상층액을 0.2filter로 여과하여 바이러스를 분리하였다.After washing the MDCK cells monolayer cultured in a 75-cm² flask with PBS, 3mL of Influenza A dilution was inoculated. After infecting the virus for 60~90 minutes at 5% CO 2 concentration and (33±2)℃ condition, add the virus culture medium and incubate the virus for (5~7) days until more than 90% of the host cells show cellular lesions. cultured. Then, the culture supernatant was centrifuged at 2000 rpm for 10 minutes, and the supernatant was filtered with 0.2 filter to separate the virus.
1.2.2. HRV 배양1.2.2. HRV culture
75-cm² flask에 단층배양한 HeLa 세포를 PBS로 세척 후, HRV 희석액 3mL를 접종하였다. 5% CO2 농도, (33±2)℃조건으로 60~90분간 바이러스를 감염시킨 후, 바이러스배양배지를 첨가하여 90% 이상의 숙주세포가 세포병변을 보일 때까지 바이러스를 3~7일간 배양하였다. 그 후 배양 상층액을 2000rpm에서 10분간 원심분리하고 상층액을 0.2filter로 여과하여 바이러스를 분리하였다.HeLa cells cultured as monolayers in a 75-cm² flask were washed with PBS, and then inoculated with 3 mL of HRV dilution. After infecting the virus for 60-90 minutes at a 5% CO 2 concentration and (33±2)℃ condition, the virus culture medium was added and the virus was cultured for 3-7 days until more than 90% of the host cells showed cellular lesions. . Then, the culture supernatant was centrifuged at 2000 rpm for 10 minutes, and the supernatant was filtered with 0.2 filter to separate the virus.
1.2.3. TGEV 배양1.2.3. TGEV culture
75-cm² flask에 단층배양한 ST 세포를 PBS로 세척 후, EMEM (w/o TPCK-treated trypsin)을 넣어 5% CO₂, (36 ± 2) ℃에 3시간 두었다. 그 후 바이러스배양배지 (w/ TPCK-treated trypsin)로 희석한 TGEV 희석액 3mL를 접종하였다. 5% CO2 농도, (33±2)℃조건으로 60~90분간 바이러스를 감염시킨 후, 바이러스배양배지를 첨가하여 90% 이상의 숙주세포가 세포병변을 보일 때까지 바이러스를 3~5일간 배양하였다. 그 후 배양 상층액을 2000rpm에서 10분간 원심분리하고 상층액을 0.2filter로 여과하여 바이러스를 분리하였다.After washing the monolayer-cultured ST cells in a 75-cm² flask with PBS, EMEM (w/o TPCK-treated trypsin) was added, and the cells were placed at 5% CO₂, (36 ± 2) °C for 3 hours. Thereafter, 3 mL of a TGEV dilution diluted with a virus culture medium (w/ TPCK-treated trypsin) was inoculated. After infecting the virus for 60-90 minutes at a 5% CO 2 concentration and (33±2)℃ condition, the virus culture medium was added and the virus was cultured for 3 to 5 days until more than 90% of the host cells showed cellular lesions. . Then, the culture supernatant was centrifuged at 2000 rpm for 10 minutes, and the supernatant was filtered with 0.2 filter to separate the virus.
1.2.4. EMCV 배양1.2.4. EMCV culture
75-cm² flask에 단층배양한 Vero 세포를 PBS로 세척 후, EMCV 희석액 3mL를 접종하였다. 5% CO2 농도, (36±2)℃조건으로 60~90분간 바이러스를 감염시킨 후, 바이러스배양배지를 첨가하여 90% 이상의 숙주세포가 세포병변을 보일 때까지 바이러스를 1~4일간 배양하였다. 그 후 배양 상층액을 2000rpm에서 10분간 원심분리하고 상층액을 0.2filter로 여과하여 바이러스를 분리하였다.After washing the Vero cells monolayer cultured in a 75-cm² flask with PBS, 3 mL of EMCV dilution was inoculated. After infecting the virus for 60-90 minutes at a 5% CO 2 concentration and (36±2)℃ condition, the virus culture medium was added and the virus was cultured for 1 to 4 days until more than 90% of the host cells showed cellular lesions. . Then, the culture supernatant was centrifuged at 2000 rpm for 10 minutes, and the supernatant was filtered with 0.2 filter to separate the virus.
1.3. 항바이러스 시험1.3. antiviral test
1.3.1. 세포독성시험1.3.1. Cytotoxicity test
바이러스배양배지를 시험용액에 1:9의 비율로 혼합한 후 (90% 시험용액), 바이러스배양지에 10배씩 단계희석하였다. 희석된 시험용액은 숙주세포에 (36 ± 1) ℃에서 30~60분간 처리한 후, 세포독성양상을 현미경을 통해 육안으로 관찰하였다.After mixing the virus culture medium with the test solution in a ratio of 1:9 (90% test solution), the virus culture medium was diluted 10-fold in steps. After the diluted test solution was treated at (36 ± 1) °C for 30 to 60 minutes, the cytotoxicity was observed visually through a microscope.
1.3.2. 세포배양 대조군1.3.2. Cell culture control
숙주세포에 바이러스배양배지를 처리하여 세포배양 대조로 사용하였다.The host cells were treated with a virus culture medium and used as a cell culture control.
1.3.3. 바이러스 대조군1.3.3. virus control
시험 바이러스를 바이러스배양배지에 1:9의 비율로 혼합하여 (22 ± 2) ℃에서 1시간 처리하였다. 이 혼합액을 바이러스 시험군의 중화방식 (1.3.4.)과 동일하게 처리한 후, 바이러스배양배지에 10배씩 단계희석하고 각 희석액을 숙주세포에 접종하였다.The test virus was mixed in a virus culture medium in a ratio of 1:9 and treated at (22 ± 2) °C for 1 hour. This mixture was treated in the same manner as in the neutralization method (1.3.4.) of the virus test group, and then diluted 10-fold in the virus culture medium, and each dilution was inoculated into host cells.
1.3.4. 바이러스 시험군1.3.4. virus test group
시험 바이러스를 시험용액에 1:9의 비율로 혼합하여 (22 ± 2) ℃에서 1시간 처리하였다. 예비시험을 통해 시험용액이 세포독성을 유발하는 것을 확인하였으므로 ASTM E1482-12에 따라 gel filtration column을 이용하여 시험용액을 중화하였다. 그 후 즉시 바이러스배양배지에 10배 단계희석한 후 각 희석액을 숙주세포에 감염시켰다.The test virus was mixed with the test solution in a ratio of 1:9 and treated at (22 ± 2) °C for 1 hour. Since it was confirmed that the test solution induces cytotoxicity through a preliminary test, the test solution was neutralized using a gel filtration column according to ASTM E1482-12. After that, immediately after 10-fold serial dilution in the virus culture medium, each dilution was infected with the host cells.
1.4. 검증 시험1.4. verification test
1.4.1. 아세포독성 (sub-cytotoxicity)1.4.1. sub-cytotoxicity
세포독성을 나타내지 않은 최고 농도의 시험용액을 숙주세포에 30분간 처리한 후 세포 단층을 PBS로 세척하고, 바이러스를 접종하였다. 그 후 5% CO2 농도, (33±2)℃조건(Influenza, HRV) 또는 (36±2)℃조건(TGEV,EMCV)으로 60~90분간 바이러스를 감염시키고 5% CO2 농도, (33±2)℃조건(Influenza, HRV) 또는 (36±2)℃조건(TGEV,EMCV)조건으로 3~10일간 배양하였다After treating the host cells with the highest concentration of the test solution that did not show cytotoxicity for 30 minutes, the cell monolayer was washed with PBS, and the virus was inoculated. After that, the virus was infected for 60-90 minutes at a 5% CO 2 concentration, (33±2) ℃ condition (Influenza, HRV) or (36±2) ℃ condition (TGEV, EMCV) and 5% CO 2 concentration, (33 Incubated for 3 to 10 days under ±2)℃ conditions (Influenza, HRV) or (36±2)℃ conditions (TGEV, EMCV).
1.4.2. 중화시험1.4.2. neutralization test
중화된 시험용액과 바이러스를 동량으로 혼합하여 (10~20)분간 반응시킨 후, 숙주세포에 접종하였다. 그 후 5% CO2 농도, (33±2)℃조건(Influenza, HRV) 또는 (36±2)℃조건(TGEV,EMCV)으로 60~90분간 바이러스를 감염시키고 5% CO2 농도, (33±2)℃조건(Influenza, HRV) 또는 (36±2)℃조건(TGEV,EMCV)조건으로 3~10일간 배양하였다The neutralized test solution and virus were mixed in equal amounts and reacted for (10-20) minutes, and then inoculated into host cells. After that, the virus was infected for 60-90 minutes at a 5% CO 2 concentration, (33±2) ℃ condition (Influenza, HRV) or (36±2) ℃ condition (TGEV, EMCV) and 5% CO 2 concentration, (33 Incubated for 3 to 10 days under ±2)℃ conditions (Influenza, HRV) or (36±2)℃ conditions (TGEV, EMCV).
1.5. 바이러스 회수1.5. Virus Recovery
반응이 끝난 각 용액을 10배씩 단계희석하고 각 단계별 희석액을, 96 well plate에 미리 준비한 세포에 100씩 8개 well에 처리하여 5% CO2 농도, (33±2)℃조건(Influenza, HRV) 또는 (36±2)℃조건(TGEV,EMCV)조건으로 3~10일간 배양하였다.Step-dilute each solution 10 times after the reaction, and treat each step-by-step dilution in 8 wells of 100 cells in a 96-well plate, 5% CO 2 concentration, (33±2)℃ condition (Influenza, HRV) or (36±2)°C conditions (TGEV, EMCV) for 3 to 10 days.
1.5.2. 염색조건1.5.2. dyeing conditions
25% Methyl alcohol (v/v), 0.5% crystal violet (w/v)의 염색시약을 세포에 처리하여 (22 ± 2) ℃에서 10분 동안 염색하였다.Cells were treated with a staining reagent of 25% methyl alcohol (v/v) and 0.5% crystal violet (w/v) and stained at (22 ± 2) °C for 10 minutes.
1.5.3. 결과 관찰1.5.3. Observe the results
Crystal violet에 의해 염색된 well의 수를 세어 Spearman-Karber법으로 역가를 산출하였다. 바이러스 역가는 1.6.1.항 수학식 1에 따라 계산하였고, 감소율은 1.6.2.항 수학식 2에 따라 결정하였다.The number of wells stained with crystal violet was counted and the titer was calculated by the Spearman-Karber method. Virus titer was calculated according to Equation 1 in Section 1.6.1., and the reduction rate was determined according to Equation 2 in Section 1.6.2.
1.6. 결과 계산1.6. Calculate the result
1.6.1. 바이러스 역가 계산 1.6.1. Virus titer calculation
[바이러스 역가 계산식][Formula for calculating virus titer]
L = X0 -(d/2) + d x Σ(ri/ni)L = X 0 -(d/2) + dx Σ(r i /n i )
L : Log10TCID50 titerL: Log 10 TCID 50 titer
X0 : Log10 of the reciprocal of the lowest dilution at which all test inocula are positiveX 0 : Log 10 of the reciprocal of the lowest dilution at which all test inocula are positive
d : Log10 of the dilution factor(that is, the difference between the log dilution intervals)d : Log 10 of the dilution factor(that is, the difference between the log dilution intervals)
ni : Number of test inocula used at each individual dilutionn i : Number of test inocula used at each individual dilution
ri : Number of positive test inocula (out of ni)r i : Number of positive test inocula (out of n i )
Σ(ri/ni) : Sum of the proportion tests beginning at the lowest dilution showing 100% positive resultΣ(r i /n i ) : Sum of the proportion tests beginning at the lowest dilution showing 100% positive result
1.6.2. 감소율 [Log reduction (LR)]의 계산 1.6.2. Calculation of reduction rate [Log reduction (LR)]
[Log reduction 계산식][Log reduction formula]
LR = MLU - MLT LR = ML U - ML T
MLU = Mean of the titers recovered from the virus control specimen(untreated)ML U = Mean of the titers recovered from the virus control specimen(untreated)
MLT = Mean of the titers recovered from virucidal test specimen(treated)ML T = Mean of the titers recovered from virucidal test specimen(treated)
단, Log값은 소수점 2자리까지 표기한다.However, log values are indicated up to 2 decimal places.
1.7. 시험 성립 조건1.7. Test completion conditions
1.7.1. 세포독성시험1.7.1. Cytotoxicity test
시험용액에 의한 숙주세포의 세포독성이 관찰되지 않아야 한다. 만약 시험용액이 직접적으로 세포독성을 유발할 경우, gel-filteration column을 이용하여 중화해야 한다.Cytotoxicity of host cells by the test solution should not be observed. If the test solution directly induces cytotoxicity, it should be neutralized using a gel-filteration column.
1.7.2. 아세포독성시험1.7.2. cytotoxicity test
육안관찰을 통해 시험용액에 의한 세포독성이 관찰되지 않았어도 시험용액이 세포의 바이러스 감염능을 증가 혹은 감소시킬 수 있기 때문에, 아세포독성 여부를 확인하여야 한다. 대조군과 비교하여 바이러스 역가가 (45 ± 5) % 이상 낮을 경우, 해당 희석배율은 감소율 산출에서 제외하였다.Although cytotoxicity by the test solution is not observed through visual observation, since the test solution can increase or decrease the virus infectivity of cells, cytotoxicity should be checked. When the virus titer was lower than that of the control by (45 ± 5) % or more, the dilution factor was excluded from the reduction rate calculation.
1.7.3. 중화시험1.7.3. neutralization test
시험용액과 바이러스의 반응이 끝난 시점에서 시험용액을 중화한 후, 중화여부를 입증하여야 한다. 만약 대조군과 비교하였을 때 바이러스의 회수가 (80 ± 5) % 보다 낮게 관찰될 경우, 충분한 중화가 이루어지지 않았으므로 gel-filteration column등의 방법을 이용하여 적절한 중화단계를 거쳐야 한다.After neutralizing the test solution at the time when the reaction between the test solution and the virus is complete, the neutralization should be verified. If the recovery of the virus is observed to be lower than (80 ± 5) % compared to the control group, sufficient neutralization has not been achieved, so an appropriate neutralization step must be performed using a method such as a gel-filteration column.
2. 결과 (Results)2. Results
2.1. 시험용액의 세포독성2.1. Cytotoxicity of the test solution
바이러스배양배지를 시험용액에 1:9의 비율로 혼합한 후 (90% 시험용액), 세포독성여부를 확인해 본 결과 모든 숙주세포에 대해 세포독성을 유발하는 것을 확인하였으므로 ASTM E1482-12에 따라 gel filtration columns을 이용하여 시험용액을 중화한 후, 시험에 사용하였다. 중화된 시험용액은 90% 농도까지 세포독성이 관찰되었다 (표 1).After mixing the virus culture medium with the test solution in a ratio of 1:9 (90% test solution), it was confirmed that cytotoxicity was caused to all host cells. After neutralizing the test solution using filtration columns, it was used for the test. The neutralized test solution showed cytotoxicity up to 90% concentration (Table 1).
세 포 숙 주
cell host
독성을 나타내지 않는 최고 희석배수(시험용액의 농도)
The highest dilution that does not show toxicity (concentration of test solution)
2.2. 항바이러스 시험 결과2.2. Antiviral test results
항바이러스 시험 결과는 다음의 표 1 및 표 2와 같다.Antiviral test results are shown in Tables 1 and 2 below.
바이러스 virus
바이러스 대조군(1시간 후) Virus control (after 1 hour)
시험군(1시간 후) Test group (after 1 hour)
Influenza A Influenza A
5.63 5.63
〈 2.50 < 2.50
HRV HRV
7.88 7.88
3.25 3.25
TGEV TGEV
6.75 6.75
4.88 4.88
EMCV EMCV
8.63 8.63
8.50 8.50
바이러스 virus
LR LR
Influenza A Influenza A
〉3.13 >3.13
HRV HRV
4.63 4.63
TGEV TGEV
1.87 1.87
EMCV EMCV
0.13 0.13
LR(Log reduction)이 1이상이면 바이러스 감소 백분율(% redution)이 90%이상이고, LR(Log reduction)이 2이상이면 바이러스 감소 백분율(% redution)이 99%이상이고, LR(Log reduction)이 3이상이면 바이러스 감소 백분율(% redution)이 99.9%이상이고, LR(Log reduction)이 4이상이면 바이러스 감소 백분율(% redution)이 99.99%이상이고, LR(Log reduction)이 5이상이면 바이러스 감소 백분율(% redution)이 99.999%이상이다. 시험 결과 모든 종류의 시험 바이러스에 대하여 유의미한 바이러스 감소율이 나왔음을 알 수 있고, 일부에서는 바이러스 감소 백분율이 99.9%이상임을 알 수 있다. If LR (Log reduction) is 1 or more, the virus reduction percentage (% redution) is 90% or more, If LR (Log reduction) is 2 or more, the virus reduction percentage (% redution) is 99% or more, LR (Log reduction) is If 3 or more, the virus reduction percentage (% redution) is 99.9% or more, if LR (Log reduction) is 4 or more, the virus reduction percentage (% redution) is 99.99% or more, and if LR (Log reduction) is 5 or more, the virus reduction percentage (% redution) is more than 99.999%. As a result of the test, it can be seen that a significant virus reduction rate was obtained for all kinds of test viruses, and it can be seen that the virus reduction percentage was more than 99.9% in some cases.
아세포독성시험 결과 및 중화시험 결과는 다음의 표 4 및 표 5와 같다. The results of the blast toxicity test and the neutralization test are shown in Tables 4 and 5 below.
바이러스 virus
대조군 control
시험군 test group
결과판정 result judgment
Influenza A Influenza A
5.63 5.63
5.38 5.38
Lack of InterferenceLack of Interference
HRV HRV
7.50 7.50
7.13 7.13
Lack of InterferenceLack of Interference
TGEV TGEV
6.75 6.75
6.50 6.50
Lack of InterferenceLack of Interference
EMCV EMCV
8.38 8.38
8.38 8.38
Lack of InterferenceLack of Interference
바이러스 virus
대조군 control
시험군 test group
결과판정 result judgment
Influenza A Influenza A
5.50 5.50
5.13 5.13
Successful neutralizationsuccessful neutralization
HRV HRV
7.13 7.13
6.88 6.88
Successful neutralizationsuccessful neutralization
TGEV TGEV
6.63 6.63
6.38 6.38
Successful neutralizationsuccessful neutralization
EMCV EMCV
8.50 8.50
8.75 8.75
Successful neutralizationsuccessful neutralization
2.2.1 Influenza A 항바이러스시험의 유효성2.2.1 Efficacy of Influenza A Antiviral Test
바이러스 대조의 역가는 5.63 log10TCID50/mL, 시험군의 역가는 < 2.50 log10 TCID50/mL로 관찰 되었다(표 2). The titer of the virus control was 5.63 log 10 TCID 50 /mL, and the titer of the test group was < 2.50 log 10 TCID 50 /mL (Table 2).
세포배양 대조에서는 역가가 관찰되지 않았고, 시험용액 (9%)의 세포독성 및 아세포독성이 관찰되지 않았으며, 중화 대조에서 시료의 중화가 확인되었으므로 본 시험의 유효성을 입증하고 있다(표 4, 표 5). No titer was observed in the cell culture control, no cytotoxicity and cytotoxicity of the test solution (9%) were observed, and the neutralization of the sample was confirmed in the neutralizing control, thus proving the effectiveness of this test (Table 4, Table 4). 5).
2.2.2 HRV 항바이러스시험의 유효성2.2.2 Efficacy of HRV antiviral test
바이러스 대조의 역가는 7.88 log10TCID50/mL, 시험군의 역가는 3.25 log10TCID50/mL로 관찰 되었다(표 2). The titer of the virus control was 7.88 log 10 TCID 50 /mL, and the titer of the test group was 3.25 log 10 TCID 50 /mL (Table 2).
세포배양 대조에서는 역가가 관찰되지 않았고, 시험용액(9%)의 세포독성 및 아세포독성이 관찰되지 않았으며, 중화 대조에서 시료의 중화가 확인되었으므로 본 시험의 유효성을 입증하고 있다(표 4, 표 5). No titer was observed in the cell culture control, no cytotoxicity and cytotoxicity of the test solution (9%) were observed, and the neutralization of the sample was confirmed in the neutralizing control, thus proving the effectiveness of this test (Table 4, Table 4). 5).
2.2.3. TGEV 항바이러스시험의 유효성2.2.3. Efficacy of TGEV antiviral test
바이러스 대조의 역가는 6.75 log10TCID50/mL, 시험군의 역가는 4.88 log10 TCID50/mL로 관찰 되었다(표 2).The titer of the virus control was 6.75 log 10 TCID 50 /mL, and the titer of the test group was 4.88 log 10 TCID50/mL (Table 2).
세포배양 대조에서는 역가가 관찰되지 않았고, 시험용액 (9%)의 세포독성 및 아세포독성이 관찰되지 않았으며, 중화 대조에서 시료의 중화가 확인되었으므로 본 시험의 유효성을 입증하고 있다(표 4, 표 5). No titer was observed in the cell culture control, no cytotoxicity and cytotoxicity of the test solution (9%) were observed, and the neutralization of the sample was confirmed in the neutralizing control, thus proving the effectiveness of this test (Table 4, Table 4). 5).
2.2.4. EMCV 항바이러스시험의 유효성2.2.4. Efficacy of EMCV antiviral test
바이러스 대조의 역가는 8.63 log10 TCID50/mL, 시험군의 역가는 8.50 log10TCID50/mL로 관찰 되었다(표 2). The titer of the virus control was 8.63 log 10 TCID 50 /mL, and the titer of the test group was 8.50 log 10 TCID 50 /mL (Table 2).
세포배양 대조에서는 역가가 관찰되지 않았고, 시험용액 (9%)의 세포독성 및 아세포독성이 관찰되지 않았으며, 중화 대조에서 시료의 중화가 확인되었으므로 본 시험의 유효성을 입증하고 있다(표 4, 표 5). No titer was observed in the cell culture control, no cytotoxicity and cytotoxicity of the test solution (9%) were observed, and the neutralization of the sample was confirmed in the neutralizing control, thus proving the effectiveness of this test (Table 4, Table 4). 5).
3. 결론 (Conclusion)3. Conclusion
본 시험 조건하에서 본원 발명의 항바이러스제 시험용액에 대한 Influenza A, HRV, TGEV 및 EMCV의 바이러스 감소율 (log reduction)은 각각 > 3.13, 4.63, 1.87, 0.13으로 확인되었다(표 3). 따라서, 본원 발명은 이들 바이러스에 대한 항바이러스능이 있음을 확인하였다. Virus reduction rates (log reduction) of Influenza A, HRV, TGEV and EMCV for the antiviral agent test solution of the present invention under these test conditions were >3.13, 4.63, 1.87, and 0.13, respectively (Table 3). Therefore, the present invention confirmed that there is antiviral activity against these viruses.
<임상시험><Clinical trial>
<B형 간염에 대한 효과 측정><Measurement of effect on hepatitis B>
GOT가 50 ~ 60U/ml 범위인 B간염 환자 남성 7명과 여성 3명에 대하여 본 발명에 따른 항바이러스제를 1회 2포씩 t.i.d로 3개월을 복용하게 하고 GOT측정을 한 결과, 1명의 남성 간염 환자를 제외하고, 나머지 9명에 대하여 모두 정상 범위인 32 ~ 38U/ml의 GOT측정 결과를 얻었다. 7 male and 3 female hepatitis B patients with GOT in the range of 50 to 60 U/ml were given the antiviral agent according to the present invention 2 sachets at a time for 3 months at t.i.d. As a result of GOT measurement, one male hepatitis patient Except for , GOT measurement results of 32 ~ 38U/ml, which are all within the normal range, were obtained for the remaining 9 patients.
<A형 인플루엔자 바이러스에 대한 효과 측정><Measurement of effect on influenza A virus>
고열, 오한, 두통, 근육통 등을 호소하는 A 형 독감환자 4인에 대하여 본 발명에 따른 항바이러스제를 각3포씩 t.i.d로 5일간 복용하게 하였다. 복용후 3일만에 3인의 체온이 정상 체온으로 돌아와 고열, 오한, 근육통이 사라졌고, 복용 5일후 간헐적 미열, 피로감, 기침, 인후통 등이 정상에 가깝게 개선된 것을 확인하였다. For 4 influenza A patients complaining of high fever, chills, headache, muscle pain, etc., 3 packets of the antiviral agent according to the present invention were administered t.i.d. for 5 days. It was confirmed that the body temperature of the three persons returned to normal body temperature within 3 days of taking the drug, and the high fever, chills, and muscle pain disappeared.
<라이노 바이러스에 대한 효과 측정><Measurement of effect on rhinovirus>
코감기(라이노 바이러스 감염)환자 여성 5명, 남성 5명 대상으로 본 발명에 따른 항바이러스제를 각1포씩 t.i.d로 5일간 복용하게 하였다. 5일 후, 여성 4명과 남성 3명에게서 코물 뿐만 아니라 코감기 증상이 완전히 사라지고, 나머지 3명의 환자들에게 콧물 증상이 현저히 완화됐음을 확인하였다.5 females and 5 males of nasal cold (rhinovirus infection) patients were instructed to take the antiviral agent according to the present invention, one pack each, t.i.d. for 5 days. After 5 days, it was confirmed that the symptoms of runny nose as well as runny nose completely disappeared in 4 women and 3 men, and the symptoms of runny nose were significantly alleviated in the remaining 3 patients.
<아데노 바이러스에 대한 효과 측정><Measurement of effect on adenovirus>
목감기(아데노 바이러스 감염)환자 여성 3명, 남성 3명 대상으로 본 발명에 따른 항바이러스제를 각2포씩 b.i.d로 4일간 복용하게 하였다. 4일 후, 3명의 환자에게서 몸감기 증상이 사라지고, 나머지 3명의 환자에게서도 목통증 등 목감기 증상이 현저히 완화됐음을 확인하였다. 3 female and 3 male patients with sore throat (adenovirus infection) were instructed to take 2 packets of the antiviral agent according to the present invention b.i.d. for 4 days. After 4 days, it was confirmed that the symptoms of the common cold disappeared in 3 patients, and the symptoms of a sore throat, such as neck pain, were remarkably alleviated in the remaining 3 patients.
<대상포진에 대한 효과 측정><Measurement of effect on herpes zoster>
대상포진으로 진단받고 1년이상 경과한 환자 3명(이하, 장기 치료 환자그룹), 대상포진으로 진단받고 1개월미만 경과한 환자 5명(단기 환자그룹)을 대상으로, 장기 치료 환자그룹에 대해서는 본 발명에 따른 항바이러스제를 2포씩 t.i.d로 2개월간 복용하게 하고, 단기 치료 환자그룹에 대해서는 1포씩 b.i.d로 1개월간 복용하게 하였다. 장기 치료 환자그룹은 2개월 복용 후 2명의 환자에게서 통증 소멸과 함께 대상포진이 완전히 사라진 것이 관찰되었다. 단기 치료 환자그룹은 1개월 복용 후 4명에게서 통증 소멸과 함께 대상포진이 더이상 관찰되지 않았다. For 3 patients who had been diagnosed with herpes zoster for more than 1 year (hereafter, long-term treatment patient group), and 5 patients who had been diagnosed with herpes zoster for less than 1 month (short-term patient group), for the long-term treatment patient group, The antiviral agent according to the present invention was to be taken for 2 months at t.i.d, 2 sachets each, and 1 sachet per b.i.d for 1 month for the short-term treatment patient group. In the long-term treatment group, it was observed that after 2 months of taking, the pain disappeared and herpes zoster completely disappeared in 2 patients. In the short-term treatment group, after 1 month of taking, 4 patients with pain disappeared and herpes zoster was no longer observed.
<건선에 대한 효과 측정><Measurement of effect on psoriasis>
건선으로 진단 받은 후 1년 이상 치료가 안된 남성 환자 3명과 여성 환자 4명에 대하여, 본 발명에 따른 본 발명에 따른 항바이러스제를 각1포씩 t.i.d로 4개월간 복용하게 하고, 4개월 후 상태를 관찰하였다. 4개월 후 남성 환자 2명과 여성 환자 2명에게서, 인설이나 홍반이 육안으로 관찰되지 않았다. 나머지 환자들에게서도 인설 및 홍반의 범위가 복용전에 비하여 1/3이하로 줄어든 것을 확인하였다. After being diagnosed with psoriasis, for 3 male and 4 female patients who had not been treated for more than 1 year, the antiviral agent according to the present invention was administered t.i.d. for 4 months, and the condition was observed after 4 months. did. After 4 months, no scales or erythema were observed in 2 male and 2 female patients. In the remaining patients, it was confirmed that the range of scale and erythema was reduced to less than 1/3 compared to before administration.
<아토피성 피부염에 대한 효과 측정><Measurement of effect on atopic dermatitis>
팔에 소양증이 수반된 아토피성 피부염이 있는 환자 5명과, 다리에 소양증이 수반된 아토피성 피부염이 있는 환자 5명을 대상으로, 본 발명에 따른 항바이러스제를 최초 1개월간은 각2포씩 t.i.d로 복용하게 하고, 1개월도과 후 3개월간 각1포씩 t.i.d로 추가 복용하게 하면서, 상태를 관찰하였다. 최초 1개월 복용 후 10명의 환자 가운데, 9명의 환자에게서 소양증이 사라졌고, 염증은 완화되었다. 3개월의 추가 복용 후, 4명의 환자에게서 염증이 더 이상 관찰되지 않았고, 3명의 환자에게는 염증 범위가 복용전에 비하여 1/4 이하로 줄어들었다. 3개월의 추가 복용 후 소양증이 남아 있는 환자는 없었다. For 5 patients with atopic dermatitis accompanied by pruritus on the arms and 5 patients with atopic dermatitis accompanied by pruritus on the legs, the antiviral agent according to the present invention was administered t.i.d. 2 sachets each for the first 1 month The condition was observed while additionally taking 1 pouch each t.i.d for 3 months after 1 month. After taking the first month, pruritus disappeared and inflammation was relieved in 9 of 10 patients. After 3 months of additional dosing, inflammation was no longer observed in 4 patients, and in 3 patients, the extent of inflammation was reduced to less than 1/4 compared to before administration. There was no pruritus remaining after 3 months of additional use.
<경부 근막동통 증후군에 대한 효과 측정)<Measurement of effect on cervical myofascial pain syndrome)
움직임이 없어도 목 통증을 느끼는 경부 근막동통 환자 10명을 선발하여, 5명(M1-M5)에게는 본 발명의 <실시 예>에 따른 환을 28일간 1회 1포씩 1일 3회 복용하게 하고, 나머지 5명(m1-m5)에게는 <비교 예>로 경부 근막동통 증후군에 일반적으로 처방되는 진통제인 타이레놀 650mg 8시간 서방제를 28일간 1회 1알씩 1일 3회 복용하게 하여 그 효과를 측정하였다. 10 patients with cervical myofascial pain who feel neck pain even without movement were selected, and 5 patients (M1-M5) were given the pill according to the <Example> of the present invention, 1 packet once for 28 days, 3 times a day, The other 5 patients (m1-m5) were given Tylenol 650 mg, an 8-hour sustained-release drug, which is commonly prescribed for cervical myofascial pain syndrome, as a <comparative example>, and the effect was measured by taking one tablet three times a day for 28 days. .
28일간의 복용 후, 움직여도 통증이 느껴지지 않은 경우 5점, 움직이지 않을 때는 통증이 느껴지지 않으나 움직일 때는 통증이 느껴지는 경우 3점, 움직이지 않아도 통증이 계속 느껴지는 경우 1점을 부여하게 하였다. After 28 days of taking, 5 points were given if no pain was felt even when moving, 3 points if no pain was felt when not moving but pain was felt when moving, and 1 point if pain was felt even when not moving.
측정 결과는 다음 표 6과 같았다. The measurement results are shown in Table 6 below.
<실시 예> 복용 환자
<Example> Patients taking
<비교 예> 복용 환자
<Comparative example> Patients taking
M1
M1
M2
M2
M3
M3
M4
M4
M5
M5
m1
m1
m2
m2
m3
m3
m4
m4
m5
m5
3
3
3
3
1
One
5
5
3
3
3
3
1
One
3
3
1
One
3
3
위 측정 결과에서 본 발명의 실시 예에 따른 환의 복용 환자의 통증 개선 정도가 비교 예에 따른 환의 복용 환자의 통증 개선 정도 보다 우수함을 알 수 있다. From the above measurement results, it can be seen that the pain improvement degree of the patient taking the pill according to the embodiment of the present invention is superior to the pain improvement degree of the patient taking the pill according to the comparative example.
<만성 족저 근막염에 대한 효과 측정)<Measurement of effect on chronic plantar fasciitis)
걷지 않아도 발다닥의 통증을 느끼는 만성 족저 근막염 환자 10명을 선발하여, 5명(M1-M5)에게는 본 발명의 <실시 예>에 따른 환을 28일간 1회 2포씩 1일 3회 복용하게 하고, 나머지 5명(m1-m5)에게는 만성 족저 근막염에 일반적으로 처방되는 진통제인 타이레놀 650mg 8시간 서방제를 28일간 1회 1알씩 1일 3회 복용하게 하여 그 효과를 측정하였다. Ten patients with chronic plantar fasciitis who felt pain in their feet even without walking were selected, and 5 patients (M1-M5) were given the pills according to <Example> of the present invention, 2 capsules, 3 times a day for 28 days, The other 5 patients (m1-m5) were given Tylenol 650 mg, an 8-hour sustained-release drug, which is a commonly prescribed pain reliever for chronic plantar fasciitis, once for 28 days, 3 times a day, and the effect was measured.
28일간의 복용 후, 움직여도 통증이 느껴지지 않은 경우 5점, 움직이지 않을 때는 통증이 느껴지지 않으나 움직일 때는 통증이 느껴지는 경우 3점, 움직이지 않아도 통증이 계속 느껴지는 경우 1점을 부여하게 하였다. After 28 days of taking, 5 points were given if no pain was felt even when moving, 3 points if no pain was felt when not moving but pain was felt when moving, and 1 point if pain was felt even when not moving.
측정 결과는 다음 표 7과 같았다. The measurement results are shown in Table 7 below.
<실시 예> 복용 환자
<Example> Patients taking
<비교 예> 복용 환자
<Comparative example> Patients taking
M1
M1
M2
M2
M3
M3
M4
M4
M5
M5
m1
m1
m2
m2
m3
m3
m4
m4
m5
m5
3
3
5
5
3
3
1
One
3
3
3
3
1
One
3
3
1
One
3
3
위 측정 결과에서 본 발명의 실시 예에 따른 환의 복용 환자의 통증 개선 정도가 비교 예에 따른 환의 복용 환자의 통증 개선 정도 보다 우수함을 알 수 있다. From the above measurement results, it can be seen that the pain improvement degree of the patient taking the pill according to the embodiment of the present invention is superior to the pain improvement degree of the patient taking the pill according to the comparative example.
<치주 질환에 대한 효과 측정><Measurement of effect on periodontal disease>
1년 이상 치은염이 지속된 환자 20명을 10명씩 A그룹과 B그룹으로 나누고, A그룹에게는 본 발명에 따른 <실시 예>를 1회1포씩 t.i.d로 3개월간 복용하게 하고, B그룹에게는 <비교 예>로 시중에 판매중인 치은염 치료제인 덴타민캡슐(일양약품)을 1일 3회 1캡슐씩 3개월간 복용하게 하면서, 치은염 정도가 가장심한 치아 1개를 선택하여 협면과 설면으로 구획한 후, Loe & Silness의 평점 기준에 따라, 정상치은은 0점, 경미한 염증과 색조변화 또는 가벼운 부종이 있으나 치주탐침에 의한 출혈이 없는 경우 1점, 중증의 염증,발적,부종, 치은의 색조변화가 있을 뿐만 아니라 치주탐침에 경한 자극으로 출혈이 있을 경우 2점, 심한 염증,발적,부종,궤양이 있으며 자연적인 출혈이 있는 경우 3점으로 평가하여, 복용전, 복용 1개월후, 복용 2개월후, 복용 3개월 후 각 그룹의 치아별 협면과 설면의 치은염 지수를 구한 뒤 평균 성적으로 산출하였다. 그 결과는 아래 표 8과 같았다. Twenty patients with gingivitis that persisted for more than one year were divided into groups A and B of 10 each, and group A was According to the present invention, the <Example> according to the present invention was taken for 3 months by tid, one package at a time, and for group B, as a <Comparative example>, dentamine capsules (Ilyang Pharm), a commercially available gingivitis treatment, 1 capsule 3 times a day After taking each tooth for 3 months, select one tooth with the most severe gingivitis and partition it into buccal and lingual surfaces. According to Loe &Silness's rating criteria, normal gingiva is 0 points, mild inflammation and color change, or mild edema. If there is no bleeding by the periodontal probe, 1 point, severe inflammation, redness, edema, and gingival color change, as well as bleeding due to mild irritation with the periodontal probe, 2 points, severe inflammation, redness, edema, and ulcer. In case of spontaneous bleeding, it was evaluated as 3 points, and the buccal and lingual gingivitis index for each tooth of each group was calculated before taking, 1 month after taking, 2 months after taking, and 3 months after taking it, and the average score was calculated. The results are shown in Table 8 below.
(평균±표준편차)just before taking
(mean ± standard deviation)
(평균±표준편차)1 month after taking
(mean ± standard deviation)
(평균±표준편차)2 months after taking
(mean ± standard deviation)
(평균±표준편차)3 months after taking
(mean ± standard deviation)
개선율(%)
Improvement (%)
A그룹-
실시 예
Group A-
Example
1.83±0.31
1.83±0.31
1.71±0.20
1.71±0.20
1.35±0.21
1.35±0.21
0.89±0.30
0.89±0.30
51.37%
51.37%
B그룹-
비교 예
(덴타민캡슐)
Group B-
comparative example
(Dentamine Capsule)
1.78±0.38
1.78±0.38
1.70±0.33
1.70±0.33
1.48±0.38
1.48±0.38
1.35±0.41
1.35±0.41
24.15%
24.15%
위 치은염 지수의 복용직전 평균값과 복용3개월후의 평균값을 이용해서 다음의 식으로 개선율(%)을 산출했다.The improvement rate (%) was calculated by the following formula using the average value of the Witch Gingivitis Index just before taking and the average value after 3 months of taking it.
개선율(%) = (복용직전 치은염지수- 복용3개월후 치은염지수)/복용직전 치은 염지수 x 100Improvement rate (%) = (Gingivitis index just before taking - Gingivitis index after 3 months of taking) / Gingivitis index just before taking x 100
위 표에서 확인할 수 있는 바와 같이, 실시 예나 비교 예 모두에서 복용기간이 늘어남에 따라 치은염지수는 점점 낮아지는 경향을 보였다. 그러나, 그 변화율은 실시예가 비교예보다 더 크게 나타났다. 특히 3개월 복용후 개선율은 본 발명의 실시예가 비교예에 비하여 거의 2배 이상인 것을 확인할 수 있었다. As can be seen in the table above, in both Examples and Comparative Examples, the gingivitis index showed a tendency to gradually decrease as the period of administration increased. However, the rate of change was larger in the example than in the comparative example. In particular, it was confirmed that the improvement rate after taking for 3 months was almost twice as high in the example of the present invention as compared to the comparative example.
<만성 방광염에 대한 효과 측정><Measurement of effect on chronic cystitis>
1) 병원에서 만성 방광염으로 진단받은 40세에서 70세의 여성들 중 최근 1개월간 빈뇨 회수가 1일 10회 - 16회의 범위이고, 야간뇨 및 절박뇨 증상이 있는 20명을 대상으로 본 발명에 따른 항바이러스제를 1회 1포씩 1일 3회 복용하게 한 후 배뇨일지를 작성하게 하여 본 발명의 효과를 평가하였다.1) Antiviral agent according to the present invention for 20 patients with symptoms of nocturia and urgency, and the frequency of urination in the last 1 month ranged from 10 to 16 times a day among women aged 40 to 70 who were diagnosed with chronic cystitis at the hospital The effect of the present invention was evaluated by making a urination diary to be taken 3 times a day, 1 sachet at a time.
표 9에 나타낸 바와 같이 일일 평균 배뇨횟수, 평균 야간뇨 횟수, 일일 평균 절박뇨횟수에서 모두 유의적으로 개선되었다. As shown in Table 9, the average daily urination frequency, the average nocturia frequency, and the average daily urgency frequency were all significantly improved.
<1회 1포씩 1일 3회 용>
<For 3 times a day, 1 sachet at a time>
복용직전
3일간 평균
just before taking
3 days average
4주 복용후
3일간 평균
4 weeks after taking
3 days average
8주 복용후
3일간 평균
8 weeks after taking
3 days average
12주 복용후
3일간 평균
12 weeks after taking
3 days average
평균 배뇨횟수/일
Average number of urinations/day
14.2회
Episode 14.2
12.1회
Episode 12.1
11.0회
11.0 episodes
9.8회
9.8 episodes
평균 야간뇨횟수/일
Average nocturia/day
3.2회
3.2 episodes
2.7회
2.7 episodes
2.2회
2.2 episodes
1.5회
1.5 times
평균 절박뇨회수/일
Average number of urgency/day
2.9회
2.9 episodes
2.3회
2.3 episodes
2.1회
2.1 episodes
1.0회
1.0 episodes
2) 병원에서 만성 방광염으로 진단받은 40세에서 70세의 여성들 중 최근 1개월간 빈뇨 회수가 1일 12회 - 18회의 범위이고, 야간뇨 및 절박뇨 증상이 있는 20명을 대상으로 본 발명에 따른 항바이러스제를 1회 2포씩 1일 3회 복용하게 한 후 배뇨일지를 작성하게 하여 본 발명의 효과를 평가하였다.2) Antiviral agent according to the present invention for 20 patients with symptoms of nocturia and urgency, with the frequency of urination ranging from 12 to 18 times a day for the past 1 month among women aged 40 to 70 who were diagnosed with chronic cystitis at the hospital The effect of the present invention was evaluated by making a urination diary to be taken 3 times a day, 2 packs at a time.
표 10에 나타낸 바와 같이 일일 평균 배뇨횟수, 평균 야간뇨 횟수, 일일 평균 절박뇨횟수에서 모두 유의적으로 개선되었다. As shown in Table 10, the average daily urination frequency, the average nocturia frequency, and the daily average urgency frequency were all significantly improved.
이 임상 예 결과, 비교적 중증의 방광염 환자에게는 복용량을 증가시킬 경우, 유의적인 개선 효과가 나타남을 확인하였다. As a result of this clinical example, it was confirmed that a significant improvement effect appeared when the dose was increased in patients with relatively severe cystitis.
<1회 2포씩 1일 3회 복용>
<Take 2 sachets at a time, 3 times a day>
복용직전
3일간 평균
just before taking
3 days average
4주 복용후
3일간 평균
4 weeks after taking
3 days average
8주 복용후
3일간 평균
8 weeks after taking
3 days average
12주 복용후
3일간 평균
12 weeks after taking
3 days average
평균 배뇨횟수/일
Average number of urinations/day
15.8회
Episode 15.8
13.0회
13.0 episodes
10.9회
10.9 episodes
8.8회
8.8 episodes
평균 야간뇨횟수/일
Average nocturia/day
3.3회
3.3 episodes
2.5회
2.5 reps
2.0회
2.0 episodes
1.5회
1.5 times
평균 절박뇨회수/일
Average urgency/day
3.0회
3.0 episodes
2.3회
2.3 episodes
1.7회
Episode 1.7
0.8회
0.8 reps
<고혈압에 대한 효과 측정><Measurement of effect on hypertension>
공복 수축기/확장기 혈압이 각각 (M1)155mmHg/125mmHg, (M2)149mmHg/120mmHg, (M3)164mmHg/128mmHg, (M4)158mmHg/122mmHg, (M5)148mmHg/115mmHg인 고혈압 남자 환자 5명과, 공복 수축기/확장기 혈압이 각각 (W1)152mmHg/115mmHg, (W2)148mmHg/119mmHg, (W3)165mmHg/126mmHg, (W4)157mmHg/121mmHg, (W5)149mmHg/121mmHg인 고혈압 여자 환자 5명을 대상으로 본원 발명에 따른 항바이러스제를 1포씩 t.i.d로 3개월간 복용하게 하고, 3개월 후 다시 공복시 혈압을 측정하였다. 측정 결과는 남자 환자 5명에 대하여, 각각 (M1)135mmHg/95mmHg, (M2)129mmHg/98mmHg, (M3)134mmHg/90mmHg, (M4)145mmHg/111mmHg, (M5)140mmHg/100mmHg이었고, 여자 환자 5명에 대하여 각각 (W1)132mmHg/85mmHg, (W2)128mmHg/90mmHg, (W3)167mmHg/130mmHg, (W4)127mmHg/89mmHg, (W5)139mmHg/109mmHg였다. 9명의 환자에게서 개인적인 혈압 강하의 편차가 있었지만, 복용전에 비하여 복용후에 혈압이 강하하였다. 많은 고혈압 환자의 경우, 바이러스 감염이 혈관 벽 등 몸 안의 특정 부위에 염증을 일으켜서 혈압을 올리는 것으로 판단되었다.Five hypertensive male patients with fasting systolic/diastolic blood pressures of (M1)155mmHg/125mmHg, (M2)149mmHg/120mmHg, (M3)164mmHg/128mmHg, (M4)158mmHg/122mmHg, (M5)148mmHg/115mmHg, respectively, and fasting systolic blood pressure /The present invention was conducted on 5 hypertensive female patients with diastolic blood pressure of (W1)152mmHg/115mmHg, (W2)148mmHg/119mmHg, (W3)165mmHg/126mmHg, (W4)157mmHg/121mmHg, (W5)149mmHg/121mmHg, respectively. Antiviral drugs were taken for 3 months each t.i.d., and fasting blood pressure was measured again after 3 months. The measurement results were (M1)135mmHg/95mmHg, (M2)129mmHg/98mmHg, (M3)134mmHg/90mmHg, (M4)145mmHg/111mmHg, (M5)140mmHg/100mmHg for 5 male patients, respectively, and 5 female patients. (W1)132mmHg/85mmHg, (W2)128mmHg/90mmHg, (W3)167mmHg/130mmHg, (W4)127mmHg/89mmHg, (W5)139mmHg/109mmHg for each person. Although there were individual differences in blood pressure drop in 9 patients, blood pressure dropped after taking the drug compared to before taking it. In many hypertensive patients, it has been determined that viral infection raises blood pressure by causing inflammation in certain parts of the body, such as the walls of blood vessels.
<당뇨에 대한 효과 측정><Measurement of effect on diabetes>
8시간 공복 상태에서 3회 측정한 평균 혈당이 각각 (P1)134mg/dl, (P2)139mg/dl, (P3)132mg/dl, (P4)131mg/dl, (P5)128mg/dl인 당뇨(제2형 당뇨) 환자 5인을 대상으로, 본 발명에 따른 항바이러스제를 각 1포씩 t.i.d로 3개월간 복용하게 하고 혈당 측정을 하였다. 그 결과, 3회 측정한 평균 혈당이 각각 (P1)133mg/dl, (P2)139mg/dl, (P3)130mg/dl, (P4)132mg/dl, (P5)125mg/dl로 큰 변화가 없었다. 이들 환자들을 대상으로 다시 본 발명에 따른 항바이러스제를 각 1포씩 t.i.d로 3개월간 더 복용하게 하고, 최초 복용 후 6개월이 지난 시점에 당뇨 검사를 다시 시행한 결과, 3회 측정 평균 혈당이 각각 (P1)120mg/dl, (P2)125mg/dl, (P3)119mg/dl, (P4)117mg/dl, (P5)124mg/dl인 측정 결과를 얻었다. 분석결과 1명의 환자를 제외하고는 대략 10% 내외의 혈당 저하를 가져온 결과 였다. 당뇨는 바이러스가 췌장의 베타세포 등에 염증을 일으켜서 혈당을 올리는 질환으로 예상하였고, 췌장의 베타세포 등에 염증을 일으키는 바이러스를 박멸했기 때문에 이와 같은 결과를 얻었다고 본다.Diabetes (P1) 134 mg/dl, (P2) 139 mg/dl, (P3) 132 mg/dl, (P4) 131 mg/dl, (P5) 128 mg/dl measured 3 times in the fasting state for 8 hours (P5) Type 2 diabetes) For 5 patients, 1 packet of the antiviral agent according to the present invention was administered t.i.d. for 3 months, and blood glucose was measured. As a result, the average blood glucose measured three times was (P1) 133 mg/dl, (P2) 139 mg/dl, (P3) 130 mg/dl, (P4) 132 mg/dl, and (P5) 125 mg/dl, respectively, and there was no significant change. . For these patients, the antiviral agent according to the present invention was again taken for 3 months at a t.i.d., one pack each, and the diabetes test was re-executed 6 months after the first dose. As a result, the average blood glucose measured three times ( P1) 120 mg/dl, (P2) 125 mg/dl, (P3) 119 mg/dl, (P4) 117 mg/dl, and (P5) 124 mg/dl were obtained. As a result of the analysis, it was a result of bringing about a decrease in blood sugar of about 10% except for one patient. Diabetes was expected to be a disease caused by a virus causing inflammation in the beta cells of the pancreas and raising blood sugar.
<개별환자에 대한 임상예><Clinical example for individual patients>
[임상시험 1] B형 간염(50세, 남)[Clinical trial 1] Hepatitis B (50 years old, male)
50세의 남자 환자로, B형 간염 바이러스에 의해 간에 염증이 생겨 피로감을 호소하고 빈혈 증상을 보이는 환자였다. 바이러스에 감염되면 우리 몸은 이를 제거하기 위해 면역반응을 일으키고 이로 인해 감염된 간세포들이 파괴되면서 간에 염증이 생기고 피로감을 느낀다. 경우에 따라 빈혈 증상이 나타나기도 한다. 이 환자에게 본 발명의 실시 예에 따른 항바이러스제를 1 단위(4.8g)씩 3 하루에 세번 3주간 복용하게 하고 간기능검사를 하였다. 그 결과 GOT와 GPT의 수치가 급격히 올라갔지만, 악화 되는 증상이나 별다른 피로감을 호소하지는 않았고 빈혈 증상도 사라졌다. 이는 B형 간염 바이러스에 감염된 간세포가 갑자기 본 발명의 항바이러스제에 노출되면서 바이러스가 퇴치되는 과정에서 바이러스에 감염된 간세포도 함께 파괴되어 간세포 내에 있던 GOT와 GPT가 혈중으로 방출되면서 오르게 된 것이다. 그 후로도 11개월간, 본 발명의 실시 예에 따른 항바이러스제를 적절히 가감하여 계속 복용하게 하였다. 11개월 후, 이 환자에 대해 B형간염 바이러스 표지자 검사를 한 결과, B형간염 바이러스 표면항원(s항원)이 전혀 검출되지 않았다.A 50-year-old male patient complained of fatigue and anemia due to liver inflammation caused by the hepatitis B virus. When infected with a virus, our body triggers an immune response to eliminate it, which destroys infected liver cells, causing inflammation in the liver and feeling tired. In some cases, symptoms of anemia may appear. This patient was given 1 unit (4.8 g) of the antiviral agent according to an embodiment of the present invention 3 times a day for 3 weeks, and liver function tests were performed. As a result, the levels of GOT and GPT increased rapidly, but they did not complain of worsening symptoms or fatigue, and the symptoms of anemia disappeared. This is because hepatitis B virus-infected hepatocytes are suddenly exposed to the antiviral agent of the present invention, and in the process of eradicating the virus, the virus-infected hepatocytes are also destroyed, and GOT and GPT in the hepatocytes are released into the blood. After that, for 11 months, the antiviral agent according to the embodiment of the present invention was appropriately added or decreased to continue taking it. After 11 months, the hepatitis B virus marker test was performed on this patient. As a result, the hepatitis B virus surface antigen (s-antigen) was not detected at all.
[임상시험 2] 대상포진(herpes zoster)(6세, 여자)[Clinical Trial 2] Herpes zoster (6 years old, female)
본 발명자가 베이징에서 만난 6살 여자 아이였는데, 이 여자 아이는 대상포진(herpes zoster)을 앓고 있었다. 이 여자 아이는 이상하게 베이징에 머무를 때는 증상이 없다가, 고향으로 내려가면 이틀 정도 후에 증상이 나타난다고 하였다. 본 발명의 실시 예에 따른 항바이러스제를 0.5 단위씩 아침 저녁으로 1일 2회 2개월간 먹게 하였다. 그 후 다시 고향에 내려갔는데, 2일이 지나도, 7일이 지나도, 그 후 10일이 지나도록 대상포진(herpes zoster) 발진이 관찰되지 않았다. 이후에도 현재까지 대상 포진이 재발하지 않고 있다.A six-year-old girl whom the inventor met in Beijing was suffering from herpes zoster. Strangely, this girl said that she had no symptoms when she was in Beijing, but showed symptoms two days later when she returned to her hometown. The antiviral agent according to an embodiment of the present invention was taken by 0.5 units in the morning and evening twice a day for 2 months. After that, I went back to my hometown, and no herpes zoster rash was observed after 2 days, 7 days, or 10 days after that. Since then, there has been no recurrence of herpes zoster. have.
[임상시험 3] 대상포진(herpes zoster)(남, 84세)[Clinical Trial 3] Herpes zoster (male, 84 years old)
84세 남성으로, 피부과에서 대상포진(herpes zoster) 치료 후 등, 어깨, 갈비뼈 통증으로 밤에 잠을 못 잘 정도로 통증이 커졌다. 대상포진(herpes zoster)은 수두-대상포진(herpes zoster)바이러스가 소아기에 수두를 일으킨 뒤 몸속에 잠복하고 있다가 다시 활성화되면서 발생하는 질병이다. 체내에 남아 있는 바이러스는 신경을 따라 이동하여 신경절에 잠복해 있다가 면역력이 약해지면 피부에서 통증이 심한 염증을 일으킨다. 본 발명의 실시 예에 따른 항바이러스제를 2 단위씩(4.8g x 2)씩 하루에 두번 3일간 복용시키고, 그 후 1 단위씩(4.8g) 하루에 세번 7일간 더 복용하게 하였다. 이 환자는, 10일이 경과한 후 통증이 완전히 사라졌다고 진술하였고, 대상포진(herpes zoster)도 흔적만 일부 남아 있을 뿐 포진 등은 더 이상 관찰되지 않았다. An 84-year-old man, after treatment for herpes zoster at a dermatologist, suffered from back, shoulder, and rib pain that became so severe that he could not sleep at night. Herpes zoster is a disease that occurs when the chickenpox-herpes zoster virus causes chickenpox in childhood and then remains dormant in the body and then reactivates. Viruses remaining in the body move along nerves and dormant in ganglia, and when immunity is weakened, painful inflammation occurs in the skin. 2 units (4.8g x 2) of the antiviral agent according to an embodiment of the present invention were taken twice a day for 3 days, and then 1 unit (4.8g) was taken three times a day for 7 days more. This patient stated that the pain had completely disappeared after 10 days had elapsed, and herpes zoster was no longer observed except for some traces of herpes zoster.
[임상시험 4] 대상포진(herpes zoster)(36세, 남자)[Clinical Trial 4] Herpes zoster (36 years old, male)
36세의 체격 건장한 남자 환자다. 대상포진(herpes zoster)에 걸려 처방약을 먹고 있는데도 통증 때문에 잠을 잘 수 없다며 진통제를 사러 왔다. 진통대 대신 본 발명의 실시 예에 따른 항바이러스제를 1회 1 단위씩 하루에 세번 3일간 복용하게 하였다. 이 환자는, 3일 후 대상포진(herpes zoster) 흔적은 남아 있는데 통증은 완전히 사라졌다고 진술하였다. 이후, 10일간 동일량으로 더 복용하게 하여 포진이 완전히 사라진 것을 육안으로 확인하였다. 잠복해 있는 수두-대상포진(herpes zoster) 바이러스를 완전히 없애기 위해 4개월간 본 발명의 실시 예에 따른 항바이러스제를 더 복용하게 하였다. A 36-year-old, strong male patient. I came to buy a pain reliever because I have herpes zoster and I can't sleep because of the pain, even though I am taking prescription drugs. Instead of an analgesic band, the antiviral agent according to an embodiment of the present invention was taken 1 unit at a time, three times a day for 3 days. The patient stated that after 3 days, signs of herpes zoster remained, but the pain had completely disappeared. Then, it was confirmed with the naked eye that herpes completely disappeared by further taking the same amount for 10 days. In order to completely eliminate the latent chickenpox-herpes zoster virus, the antiviral agent according to the embodiment of the present invention was further taken for 4 months.
[임상시험 5] 대상포진(herpes zoster)(60세, 여자)[Clinical Trial 5] Herpes zoster (60 years old, female)
몇 년 전에 대상포진(herpes zoster)으로 1년 가까이 고생한 환자다. 동일한 부위가 다시 콕콕 쑤신다고 병원에서 대상포진(herpes zoster) 항바이러스제인 가바펜틴 처방을 받아 왔다. 본 발명의 실시 예에 따른 항바이러스제를 2 단위씩 하루에 세번 3일간 복용하게 하였다. 다음날 통증이 바로 사라져 병원 처방약을 안 먹겠다고 했다. 신경세포에 잠복해 있는 수두-대상포진(herpes zoster) 바이러스를 완전히 없애기 위해 6개월간 본 발명의 실시 예에 따른 항바이러스제를 더 복용하게 하였다.A few years ago, a patient suffered from herpes zoster for nearly a year. I have been prescribed gabapentin, an antiviral drug for herpes zoster, at the hospital saying the same area is tingling again. 2 units of the antiviral agent according to an embodiment of the present invention were taken three times a day for 3 days. The next day, the pain disappeared immediately, and I decided not to take the hospital prescription medication. In order to completely eliminate the varicella-zoster virus dormant in nerve cells, the antiviral agent according to the embodiment of the present invention was further taken for 6 months.
[임상시험 6] 인플루엔자(influenza)(63세, 남자)[Clinical trial 6] Influenza (63 years old, male)
신종플루(H1N1) 증상으로 병원에서 타미플루를 처방받아 1주일간 복용한 환자였다. 타미플루에 의한 증상 개선이 미미하다고 하여, 본 발명의 실시 예에 따른 항바이러스제를 2 단위씩 하루에 세번 1주일간 복용하게 하였다. 1주일 후 증세 개선이 뚜렷하여, 복용량을 각1 단위씩 하루에 세번 1주일간 더 복용하게 하였다. 2주후, 이 환자는 신종플루 증상이 완전히 사라졌다고 진술하였다. It was a patient who was prescribed Tamiflu for 1 week due to symptoms of H1N1 flu. Since the symptom improvement due to Tamiflu was insignificant, 2 units of the antiviral agent according to an embodiment of the present invention were taken three times a day for one week. After 1 week, symptom improvement was evident, and the dose was increased by 1 unit each three times a day for 1 week. Two weeks later, the patient stated that the H1N1 flu symptoms had completely disappeared.
[임상시험 7] 인플루엔자(influenza)(56세, 남자)[Clinical Trial 7] Influenza (56 years old, male)
인플루엔자 B 바이러스 감염에 의해 고열과 전신 통증을 호소하는 인플루엔자(influenza)환자였다. 본 발명의 실시 예에 따른 항바이러스제를 2 단위씩 하루에 세번 3일간 복용하게 하였다. 이 환자는, 3일후 증상이 많이 개선되었다고 진술하였다. 이후, 1주일간 1 단위씩 하루에 두번 더 복용하게 하였다. 이 환자는, 복용시작 10일 후 증상이 완전히 사라졌다고 진술하였다. It was an influenza patient who complained of high fever and general pain due to influenza B virus infection. 2 units of the antiviral agent according to an embodiment of the present invention were taken three times a day for 3 days. This patient stated that his symptoms improved significantly after 3 days. After that, 1 unit was taken twice a day for 1 week. This patient stated that the symptoms completely disappeared 10 days after starting the treatment.
[임상시험 8] 코감기(45세, 여자)[Clinical trial 8] Nasal cold (45 years old, female)
평소에 코감기에 한 번 걸리면 잘 낫지 않고 오래간다는 여자 환자였다. Rhinovirus에 감염된 환자였다. 본 발명의 실시 예에 따른 항바이러스제 1 단위씩 하루에 세번 3일간 복용하게 하였다. 이 환자는, 3일 만에 감기 증상이 완전히 사라졌다고 진술하였다.It was a female patient who said that if she usually catches a cold once, it doesn't get better and lasts a long time. The patient was infected with Rhinovirus. One unit of the antiviral agent according to an embodiment of the present invention was taken three times a day for 3 days. This patient stated that the cold symptoms completely disappeared within 3 days.
[임상시험 9] 코감기(21세, 여자)[Clinical trial 9] Nasal cold (21 years old, female)
시험을 앞둔 여자 환자였다. 먹고 졸리지 않는 감기약을 찾았다. 본 발명의 실시 예에 따른 항바이러스제를 1 단위씩 하루에 세번 6일간 복용하게 하였다. 2일간 복용 후 콧물이 더 심해졌다고 불평하였으나, 계속 복용하게 하였다. 이 환자는, 4일째부터 콧속이 뚫리고, 머리도 맑아 졌고, 6일간 복용 후 감기 증상이 완전히 사라졌다고 진술하였다. It was a female patient who was about to be tested. I found a cold medicine that doesn't make me sleepy. One unit of the antiviral agent according to an embodiment of the present invention was taken three times a day for 6 days. After taking it for 2 days, he complained that his runny nose got worse, but he continued to take it. This patient stated that from the 4th day, the nasal passages were pierced, the head became clear, and the cold symptoms completely disappeared after taking it for 6 days.
[임상시험 10] 목감기(48세, 남자)[Clinical trial 10] Sore throat (48 years old, male)
목감기에 걸린 남자 환자였다. Adenovirus에 감염된 환자였다. 본 발명의 실시 예에 따른 항바이러스제를 1 단위씩 하루에 두번 3일간 복용하게 하였으나, 에어콘이 낮은 온도로 틀어진 사무실에서 일했기 때문에 감기 증상이 개선되지 않았다. 본 발명의 실시 예에 따른 항바이러스제를 2 단위씩 하루에 세번 증량하여 3일간 더 복용하게 하였다. 이 환자는, 3일 후 목의 감기 증상이 사라졌다고 진술하였다. It was a male patient with a sore throat. The patient was infected with adenovirus. Although one unit of the antiviral agent according to an embodiment of the present invention was taken twice a day for 3 days, the cold symptoms did not improve because the air conditioner worked in an office with a low temperature. The antiviral agent according to an embodiment of the present invention was increased by 2 units three times a day to be taken for 3 more days. This patient stated that the symptoms of a cold in the throat disappeared after 3 days.
[임상시험 11] 목감기(40세, 여자)[Clinical Trial 11] Sore throat (40 years old, female)
40세 여자 환자로 밤낮이 바뀐 생활을 하는 환자였다. Adenovirus에 감염된 환자였다. 계속된 목감기로 병원에 여러 번 내원 하였고, 병원에 내원 할 때마다 계속 링거를 맞았으나, 증상의 차도가 없어 불 만족하던 환자였다. 본 발명의 실시 예에 따른 항바이러스제를 1 단위씩 하루에 세번 3일간 복용하게 하였다. 이 환자는, 2일째부터 아침에 일어나기가 훨씬 편하고, 감기 증상도 많이 좋아졌고, 1주일 만에 감기 증상이 완전히 사라졌다고 진술했다. It was a 40-year-old female patient whose life changed day and night. The patient was infected with adenovirus. He visited the hospital several times due to a continuous sore throat, and he continued to receive Ringer every time he visited the hospital, but he was dissatisfied because his symptoms did not improve. One unit of the antiviral agent according to an embodiment of the present invention was taken three times a day for 3 days. This patient stated that from the second day, it was much easier to get up in the morning, the cold symptoms improved a lot, and the cold symptoms completely disappeared within a week.
[임상시험 12] 만성 가래(73세, 남자)[Clinical trial 12] Chronic sputum (73 years old, male)
73세 남성인 이 환자는 가래가 계속 끓는다고 병원 처방약을 3년 이상 장기간 복욕해 오던 환자이다. 본 발명의 실시 예에 따른 항바이러스제를 1회 1 단위씩 하루에 세번 7일간 복용하게 하였다. 그 결과, 가래의 양이 현저하게 줄어들었다. 이 환자에게 1 단위씩 하루에 두번 3개월간 더 복용하게 하였다. 3개월간의 추가 복용 후, 이 환자는 더 이상 가래가 발생하지 않는다고 진술하였다. 점막에 발생하는 만성 질환은 대부분 바이러스성 질환일 가능성이 클 것으로 예측하여 처방한 결과이다. This 73-year-old male patient has been taking hospital prescription drugs for more than three years because his sputum is still boiling. The antiviral agent according to an embodiment of the present invention was taken 1 unit at a time, three times a day for 7 days. As a result, the amount of sputum was significantly reduced. This patient was instructed to take 1 unit twice a day for an additional 3 months. After an additional 3 months of dosing, the patient stated that she no longer had sputum. Most of the chronic diseases occurring in the mucous membranes are the result of prescribing with a high possibility of viral diseases.
[임상시험 [Clinical trial 1313 ] 건선(psoriasis)(38세, 남자)] Psoriasis (38 years old, male)
이 환자는 8년 전에 피부 병변이 시작되어, 병원에서 건선(psoriasis)으로 진단받고 지속적으로 치료를 받아왔다. 전신 피부에 골고루 건선(psoriasis)의 특징인 홍반성 피부병변을 심하게 보이는 상태였다. 초기에 본 발명의 실시 예에 따른 항바이러스제를 1 단위씩 하루에 세번 3개월간 복용하게 하였다. 복용 1-2주 후에 피부 병변이 온몸에 가득 돋아나고 12주가 지나면서 많이 개선되었다. 6개월 후 인설이나 홍반이 더 이상 육안으로 관찰되지 않았다. 건선(psoriasis)은 경계가 분명한 은백색의 인설로 덮여있는 홍반성 피부병변으로 한번 발병하면 평생 반복될 가능성이 많은 대표적인 만성 피부질환이며 원인은 확실하게 밝혀지지 않았다. This patient had been diagnosed with psoriasis at the hospital, where skin lesions began 8 years ago, and he has been receiving continuous treatment. He had severe erythematous skin lesions characteristic of psoriasis evenly over the entire skin. Initially, one unit of the antiviral agent according to an embodiment of the present invention was taken three times a day for 3 months. After 1-2 weeks of taking, skin lesions began to grow all over the body, and after 12 weeks, there was a lot of improvement. After 6 months, scales or erythema were no longer observed with the naked eye. Psoriasis is an erythematous skin lesion covered with silvery-white scales with clear boundaries. Once onset, it is a representative chronic skin disease that is likely to recur throughout life. The cause is unknown.
[임상시험 [Clinical trial 1414 ] 건선(psoriasis)(31세, 여자)] Psoriasis (31 years old, female)
본 발명의 실시 예에 따른 항바이러스제에 의한 관리 전 20년 전부터 피부병변이 시작하여 다니는 병원마다 건선(psoriasis)으로 진단을 받았다. 전신 피부에 골고루 건선(psoriasis)의 특징인 홍반성 피부병변을 심하게 보이는 상태였다. 본 발명의 실시 예에 따른 항바이러스제를 복용량을 적절히 조절하면서 3개월간 복용하게 하였다. 복용 1-2주만에 증상이 심하져 피부병변이 온몸에 가득 돋아나고 3-4주가 지나면서 점차 홍반과 인설이 사라지는 것이 관찰되었다. 24개월간 본 발명의 실시 예에 따른 항바이러스제의 복용량을 적절히 가감하면서 복용하게 한 결과 피부에 더 이상 홍반이나 인설이 육안으로 관찰되지 않게 되었다. 본 발명의 실시 예에 따른 항바이러스제가 건선(psoriasis)을 일으키는 원인인 바이러스를 모두 제거한 것으로 생각박멸한 결과라고 판단되었다.Skin lesions started from 20 years ago before management with the antiviral agent according to an embodiment of the present invention, and each hospital was diagnosed with psoriasis. He had severe erythematous skin lesions characteristic of psoriasis evenly over the entire skin. The antiviral agent according to an embodiment of the present invention was taken for 3 months while appropriately adjusting the dosage. Within 1-2 weeks of taking, the symptoms worsened, and skin lesions appeared all over the body, and erythema and scales gradually disappeared after 3-4 weeks. As a result of taking the dose of the antiviral agent according to an embodiment of the present invention appropriately for 24 months, erythema or scale was no longer observed with the naked eye. It was determined that the antiviral agent according to an embodiment of the present invention was the result of erasing all the viruses that cause psoriasis.
[임상시험 [Clinical trial 1515 ] 건선(psoriasis)(55세, 남자)] Psoriasis (55 years old, male)
수년 전부터 이발을 할 때마다 이발사에 의하여 머리 뒷쪽 두피로부터 뒷목 경계 부위까지 인설로 덮여 있는 경계가 뚜렷한 홍반성 피부 병변이 손바닥 반만한 넓이로 퍼져 있다고 지적을 들어왔던 환자이다. 건선(psoriasis)으로 판단되어, 본 발명의 실시 예에 따른 항바이러스제를 1 단위씩 하루에 두번 1개월간 복용하게 하였다. 1개월 후 경계가 줄어든 것이 현저하게 관찰되었다. 1개월 후부터 양을 늘려 본 발명의 실시 예에 따른 항바이러스제를 1 단위씩 하루에 세번 3개월간 더 복용하게 하였다. 3개월 후, 홍반은 거의 사라지고 주변의 피부색과 거의 구별이 가지 않을 정도가 되었다. 건선(psoriasis) 원인 바이러스의 완치를 위해 본 발명의 실시 예에 따른 항바이러스제를 1회 1 단위씩 하루에 두번 3개월간 더 복용하게 하였다. This is a patient who has been pointed out by the barber for several years every time a haircut is done that a well-demarcated erythematous skin lesion that is covered with scales from the scalp on the back of the head to the border of the back of the neck spreads about half the size of the palm of the hand. It was judged to be psoriasis, and 1 unit of the antiviral agent according to an embodiment of the present invention was taken twice a day for 1 month. After 1 month, a marked decrease in borderline was observed. After 1 month, the amount was increased and the antiviral agent according to an embodiment of the present invention was taken by 1 unit three times a day for 3 more months. After 3 months, the erythema had almost disappeared and became almost indistinguishable from the surrounding skin color. In order to cure the virus causing psoriasis, the antiviral agent according to an embodiment of the present invention was taken 1 unit at a time, twice a day for 3 more months.
[임상시험 16] 아토피 피부염(atopic dermatitis)(36세, 남자)[Clinical trial 16] Atopic dermatitis (36 years old, male)
어릴 때부터 아토피가 있었지만 크게 증상이 없다가 3년 전부터 이마와 손목, 뒤목 등에서 증상이 나타나고 1년 반전부터 갑자기 심해지기 시작하여 현재는 온 몸이 전체적으로 심한 증상의 환자였다. 병원에서 아토피 피부염(atopic dermatitis)으로 진단하였다. 피부가 심하게 가렵고 건조해서 당기고 심한 곳은 갈라져서 피가 나고 아픈 증상이 심해서 잠을 자지 못할 정도여서 이틀에 한 번씩 욕조에 따뜻한 물을 받고 또 뜨거운 물을 조금씩 나오게 하여 식지 않도록 하고 그 안에 들어가서 몇 시간씩 잠을 잤다고 한다. 아토피가 심해서 다니던 직장도 이미 퇴직한 상태이다. 처음 2개월간 본 발명의 실시 예에 따른 항바이러스제 2 단위씩을 하루에 세번 복용하게 한 후, 추가적으로 7개월간 1회 1 단위씩 하루에 세번 복용하게 하였다. 최초 복용 후 7-14일 사이에 증상이 심해진 듯했지만, 중단하지 않고 치료를 계속하였다. 9개월 후 이 환자의 피부에서 아토피 증상을 관찰할 수 없었고, 환자도 더 이상 가려움을 느끼지 않는다고 진술하였다. I had atopic dermatitis since I was a child, but there were no major symptoms. From 3 years ago, symptoms appeared on the forehead, wrists, and back of the neck, and suddenly started to get worse from the reverse of 1 year, and now the whole body is a patient with severe symptoms. He was diagnosed with atopic dermatitis at the hospital. The skin is very itchy and dry, pulling, cracking in severe areas, bleeding, and the symptoms are so severe that I can't sleep, so I get warm water in the bathtub every two days and pour out the hot water little by little to keep it from getting cold. said to have slept His atopy was so severe that he had already retired from his job. For the first 2 months, 2 units of the antiviral agent according to an embodiment of the present invention were taken three times a day, and then 1 unit was taken three times a day for an additional 7 months. The symptoms seemed to get worse between 7-14 days after the first dose, but the treatment was continued without stopping. After 9 months, no atopic symptoms could be observed in this patient's skin, and the patient stated that he no longer felt itching.
[임상시험 17] 아토피 피부염(atopic dermatitis)(48세, 남자)[Clinical trial 17] Atopic dermatitis (48 years old, male)
이 남자는 얼굴에 심한 아토피 피부염(atopic dermatitis)을 가진 환자였다. 이 환자는 피부과 병원에서 처방된 항히스타민제와 면역억제제를 복용했지만 증상이 개선되지 않았다. 얼굴이 빨갛게 부어 있는 이 환자에게 본 발명의 실시 예에 따른 항바이러스제를 2 단위씩 하루에 세번 7일간 복용하게 하였다. 7일후, 빨갛게 부어 있는 피부가 진정이 되고 얼굴색이 정상으로 돌아왔다. 위 효과를 확인한 후, 본 발명의 실시 예에 따른 항바이러스제를 1회 1 단위씩 하루에 세번 6개월간 복용하게 하였다. 본 발명의 적용을 시작한 후 얼굴이 빨갛게 부어 오르는 아토피 피부염(atopic dermatitis) 증상은 더 이상 발생하지 않았고, 6개월 복용 후 아토피 피부염(atopic dermatitis)의 다른 증상도 사라진 것을 육안으로 확인하였다.This man was a patient with severe atopic dermatitis on the face. The patient took antihistamines and immunosuppressants prescribed by a dermatologist, but his symptoms did not improve. This patient with a red and swollen face was instructed to take 2 units of the antiviral agent according to an embodiment of the present invention three times a day for 7 days. After 7 days, the red, swollen skin calmed down and the color of the face returned to normal. After confirming the above effect, the antiviral agent according to an embodiment of the present invention was taken 1 unit at a time three times a day for 6 months. After starting the application of the present invention, the symptoms of atopic dermatitis in which the face becomes red and swollen did not occur anymore, and it was visually confirmed that other symptoms of atopic dermatitis disappeared after taking it for 6 months.
[임상시험 18] 아토피 피부염(atopic dermatitis)(17세, 여자)[Clinical trial 18] Atopic dermatitis (17 years old, female)
이 환자는 17살 여고생으로, 무릎 뒤와 허벅지에 아토피 피부염(atopic dermatitis)가 발생한 환자였다. 본 발명의 실시 예에 따른 항바이러스제를 2 단위씩 하루에 세번 14일간 복용하게 하였다. 처음에는 예상대로 증상이 악화 되다가 점차 개선되었다. 이후, 아토피 피부염(atopic dermatitis)의 원인 바이러스를 완치하기 위하여 본 발명의 실시 예에 따른 항바이러스제를 1회 1 단위씩 하루에 두번 6개월간 더 복용하게 하였다. 6개월 복용 후 무릎 뒤와 허벅지뿐만 아니라 다른 부위에서도 아토피 피부염(atopic dermatitis) 증상이 관찰되지 않았다. This patient, a 17-year-old high school girl, had atopic dermatitis on the back of the knee and thigh. 2 units of the antiviral agent according to an embodiment of the present invention were taken three times a day for 14 days. At first, as expected, the symptoms worsened, but gradually improved. Thereafter, in order to cure the virus causing atopic dermatitis, the antiviral agent according to an embodiment of the present invention was taken 1 unit at a time, twice a day for another 6 months. After 6 months of taking, no symptoms of atopic dermatitis were observed in the back of the knee and thigh as well as in other areas.
[임상시험 19] 백반증(34세, 남자)[Clinical trial 19] Vitiligo (34 years old, male)
이 환자는 백반증의 증상이 특히 얼굴과 손, 팔목에 심하고 몸 천체에도 골고루 퍼져있는 상태여서 정상적인 사회생활이 곤란한 정도였다. 특히 백반증이 진행된 눈꺼풀의 속눈썹이 몇 가닥 하얗게 되어 있었다. 본 발명의 실시 예에 따른 항바이러스제를 적절히 가감하여 24개월간 복용하게 하였다. 24개월 후 육안으로 관찰한 결과, 백반증의 증상(백색 반점)은 피부에서 대부분 사라졌지만 하얗게 변했던 눈썹은 그대로 남아 있었다. 백반증은 정확한 원인은 알려져 있지 않지만 멜라닌 세포의 파괴로 인하여 피부에 여러 가지 크기의 백색 반점이 나타나는 후천적 탈 색소성 질환이다. 또 치료하기 위해 여러 가지 방법을 시도하지만 완전하게 치료하기가 어려운 질환이다. 백반증의 증상을 살펴보면 탈색되어 백색 반점이 있는 주위의 피부는 오히려 멜라닌 색소가 많이 분비되어 정상피부보다 검은 색을 띤다. 전형적인 바이러스에 의한 염증의 형태는 아니지만 임상 경험을 토대로 멜라닌 세포가, 멜라닌 세포에 감수성이 있는 바이러스에 감염되어 생기는 피부질환이라고 추측하였다. 멜라닌세포가 바이러스 감염으로 죽으면 멜라닌 색소를 분비하지 못하여 백반증을 일으키지만 죽기 전까지는 바이러스에 의한 염증 자극으로 멜라닌 색소를 더 많이 분비하여 주변의 피부가 검게 변하는 것으로 추측된다. 따라서 백반증의 치유과정은 먼저 원인인 바이러스를 박멸하는 것이다. 이후 멜라닌 세포가 정착하도록 피부 환경을 만들어 유지하는 것이다. 그러면 치유과정이 거의 끝나가는 시기에 백색 반점이 정상적인 살색이 되고 동시에 주변의 검은 피부도 살색으로 돌아가면서 치유가 된다. 백반증의 치유에는 경험상 12-24개월 정도의 긴 시간이 필요하고 개선효과는 초기에 나타나지 않고 치유가 거의 끝나갈 때 나타나기 시작하는 질환이다. In this patient, the symptoms of vitiligo were particularly severe on the face, hands, and wrists, and were spread evenly throughout the body, making it difficult to lead a normal social life. In particular, some of the eyelashes on the eyelids where vitiligo had progressed had turned white. The antiviral agent according to an embodiment of the present invention was appropriately adjusted and taken for 24 months. As a result of visual observation after 24 months, most of the symptoms of vitiligo (white spots) disappeared from the skin, but the white eyebrows remained. Although the exact cause is unknown, vitiligo is an acquired depigmentation disease in which white spots of various sizes appear on the skin due to the destruction of melanocytes. It is also a disease that is difficult to completely cure, although various methods are tried to treat it. If you look at the symptoms of vitiligo, the skin around the skin with white spots due to discoloration secretes a lot of melanin, which is darker than normal skin. Although it is not a typical form of viral inflammation, it was speculated that melanocytes are a skin disease caused by infection with a virus sensitive to melanocytes based on clinical experience. When melanocytes die due to virus infection, they cannot secrete melanin pigment and cause vitiligo, but until they die, it is presumed that the surrounding skin turns black by secreting more melanin pigment due to inflammatory stimulation by the virus. Therefore, the healing process of vitiligo is to first eradicate the virus that is the cause. It is to create and maintain a skin environment for melanocytes to settle thereafter. Then, when the healing process is almost finished, the white spots become normal flesh color, and at the same time, the surrounding dark skin returns to the flesh color and is healed. The treatment of vitiligo requires a long time of 12-24 months in experience, and the improvement effect does not appear at the initial stage and begins to appear when the healing is almost complete.
[임상시험 20] 만성 비염(40세, 여자)[Clinical trial 20] Chronic rhinitis (40 years old, female)
만40세의 여자로 만성 비염으로 인해 콧속 점막이 항상 부어있어서 잠을 잘 때 가습기를 틀지 않으면 잠을 자기 힘들 정도였다. 본 발명의 실시 예에 따른 항바이러스제를 각 1 단위씩 하루에 두번 12주간 복용하게 하였다. 3주째부터 숨쉬기가 편해지고, 코속 점막이 눈에 띄게 줄어들어 있었고, 코가 많이 편한 것을 느끼기 시작하였고, 12주 후 환자는 이전의 만성 비염을 더 이상 느끼지 않는다고 진술하였다. 부비강과 기도는 외부 공기와 맞닿는 부위로 바이러스와 세균에 쉽게 노출되는 부위여서 감염되기 쉽다. 세균 감염으로 인한 질환은 항생제의 발달로 개선되어 결핵을 제외하면 만성 질환으로 진행되는 경우는 드물다. 하지만 바이러스 감염 시에는 바이러스를 사멸할 수 있는 항바이러스제의 개발이 미미하여 적절한 치료가 이루어지기 힘든 상태이므로 만성 비염이나 천식 그리고 편도선비대와 같은 질환을 일으킨다. 이때 본 발명의 실시 예에 따른 항바이러스제를 복용하면 부비강이나 기도에 감염되어 염증을 일으키는 바이러스를 없애 염증은 줄어들어서 만성 비염, 천식, 편도선 비대 등이 개선된다.As a 40-year-old woman, the mucous membrane of the nose was always swollen due to chronic rhinitis, so it was difficult to sleep unless a humidifier was turned on while sleeping. Antiviral agents according to an embodiment of the present invention were taken twice a day for 12 weeks, each 1 unit. From the 3rd week onward, breathing became easier, the nasal mucosa was noticeably reduced, and the nose began to feel very comfortable. After 12 weeks, the patient stated that he no longer felt the previous chronic rhinitis. The sinuses and airways are areas that come into contact with the outside air and are easily exposed to viruses and bacteria, so they are easy to get infected. Diseases caused by bacterial infection have been improved with the development of antibiotics, and, with the exception of tuberculosis, it is rare to progress to chronic diseases. However, in the case of viral infection, the development of antiviral agents that can kill the virus is insignificant and it is difficult to obtain an appropriate treatment, so it causes diseases such as chronic rhinitis, asthma, and tonsillitis. At this time, if the antiviral agent according to an embodiment of the present invention is taken, the virus that infects the sinuses or airways and causes inflammation is eliminated, and inflammation is reduced, thereby improving chronic rhinitis, asthma, and tonsil hypertrophy.
[임상시험 21] 인후통(60세, 여자)[Clinical trial 21] Sore throat (60 years old, female)
이 환자는 목이 계속 조이고 걸린 것처럼 불편하고 아픈 상태가 6개월 이상 지속되었다. 목에 혹이 있는지 검사도 해보았으나 혹은 없었으며, 이비인후과를 2개월 다니며 치료해봐도 차도가 없었다. 이에 본 발명의 실시 예에 따른 항바이러스제를 각 1 단위씩 하루에 세번 7일간 복용하게 하였다. 7일 후 이 환자는 목의 불편한 증상이 사라지고, 잠도 편하게 잘 자게 되었다고 진술하였다. 목 점막의 바이러스 감염증이었을 가능성이 매우 크다고 판단했다. This patient had an uncomfortable and painful condition that continued for more than 6 months as if her neck was constantly tightened and stuck. I also checked for lumps in the neck, but there was no or no, and even after visiting the otolaryngologist for 2 months, there was no improvement. Accordingly, each 1 unit of the antiviral agent according to an embodiment of the present invention was taken three times a day for 7 days. After 7 days, the patient stated that the uncomfortable symptoms of the neck disappeared and that he was able to sleep comfortably. It was determined that the possibility of a viral infection of the throat mucosa was very high.
[임상시험 22] 만성위염(chronic gastritis)(54세, 여자)[Clinical trial 22] Chronic gastritis (54 years old, female)
이 환자는 여자 약사로, 만성위염에 따른 소화불량과 체증 등으로 오랫동안 고생한 환자다. 본 발명의 실시 예에 따른 항바이러스제를 1 단위씩 하루에 두번 4주간 복용하게 하였다. 이 환자는, 복용 2주 후부터 식후 소화불량 증상이 사라지고, 더 이상 음식을 먹고 체하는 증상이 없어졌다고 진술하였다. 위점막은 외부에서 음식물이 직접 들어가는 부위로 비점막이나 기도와 마찬가지로 바이러스의 침범에 취약한 부위이다. 따라서 위아토니(gastric atony), 만성위염(chronic gastritis), 위궤양 등의 소화기 질환이 악물 치료로 깨끗하게 낫지 않고 반복적으로 지속 되는 경우, 바이러스에 의한 감염증을 의심할 필요가 있다. 위산분비억제제와 항생제로도 잘 개선되지 않는 만성위염(chronic gastritis)과 위궤양, 위장관 운동조절제로 잘 개선되지 않고 반복되는 위아토니(gastric atony) 등에 본 발명의 실시 예에 따른 항바이러스제를 복용하게 하여 좋은 임상 사례를 다수 얻었다. This patient is a female pharmacist who has suffered from indigestion and congestion for a long time due to chronic gastritis. One unit of the antiviral agent according to an embodiment of the present invention was taken twice a day for 4 weeks. This patient stated that the symptoms of indigestion after eating disappeared after 2 weeks of taking the drug, and the symptoms of eating and sieving were no longer there. The gastric mucosa is a site where food enters directly from the outside, and like the nasal mucosa and airways, it is vulnerable to virus invasion. Therefore, when gastrointestinal diseases such as gastric atony, chronic gastritis, and gastric ulcer persist repeatedly without being cured with malignant treatment, it is necessary to suspect a viral infection. It is good to take the antiviral agent according to the embodiment of the present invention, such as chronic gastritis and gastric ulcer, which is not improved well even with gastric acid secretion inhibitors and antibiotics, and repeated gastric atony that does not improve well with gastrointestinal motility regulators. A number of clinical cases were obtained.
[임상시험 23] 알러지(allergy)(55개월, 남자)[Clinical trial 23] Allergy (55 months, male)
이 환자는 만 55개월의 남자 아이였다. 태어날 때부터 음식 알러지(allergy)를 많이 겪었고 (사과껍질, 복숭아, 자두, 과일류, 새우, 갑각류, 조개류, 계란, 견과류 등) 한번 배탈이 나면 응급실에서 링겔을 맞아야 할 정도로 위장관마비 및 심한 탈진이 자주 나타났다. 이에 더하여, 알러지(allergy)성 콧물 비염이 지속 되고 감기에 걸리면 잘 낫지 않고 눈은 알러지(allergy)성 결막염 때문에 눈을 자주 비벼서 늘 충혈이 되어 있었다. 본 발명의 실시 예에 따른 항바이러스제를 1 단위씩 믹서기로 갈아서 요거트와 ?은 후 하루에 두번 4주간 복용하게 하였다. 먹은 지 3일 만에 염증 있는 누런 콧물이 맑은 콧물로 바뀌고 간지러움이 덜해 눈을 비비지 않게 되어 충혈도 사라진 것을 육안으로 관찰할 수 있었다. 현재, 알러지(allergy)는 바이러스성 질환으로 알려져 있다. This patient was a 55-month-old boy. I have suffered a lot of food allergies from birth (apple peel, peaches, plums, fruits, shrimp, crustaceans, shellfish, eggs, nuts, etc.) appeared frequently. In addition, allergic (allergic) runny nose rhinitis persists and does not heal well when caught with a cold, and the eyes are always red due to frequent rubbing of the eyes due to allergic conjunctivitis. One unit of the antiviral agent according to an embodiment of the present invention was ground with a blender and mixed with yogurt, and then taken twice a day for 4 weeks. After 3 days of eating, it was possible to observe with the naked eye that the inflamed yellow runny nose changed to a clear runny nose, and the itching was reduced, so that the eyes did not rub, and the redness disappeared. Currently, allergy is known as a viral disease.
[임상시험 24] 섬유근육통(fibromyalgia)(59세, 여자)[Clinical trial 24] fibromyalgia (59 years old, female)
이 환자는, 허리, 어깨, 팔, 다리가 아프고 쑤시고 저리고 몸 전체가 안 아픈 곳이 없다고 호소하는 만성 통증 환자였다. 저녁에는 고단해서 파김치가 된다고 하였다. 본 발명의 실시 예에 따른 항바이러스제를 1 단위씩 하루에 두번 4주간 복용하게 하였다. 이 환자는, 복용 3일째부터 몸이 가벼워지고 통증이 사라지기 시작했으며, 어느 순간부터 저린 곳, 아픈 곳이 전혀 없게 되었다고 진술하였다. 이 환자는 몸의 여러 부위가 바이러스에 감염되어 있었던 것으로 의심되었다.This patient was a chronic pain patient who complained of pain in the back, shoulder, arm, and leg, and complaining that there was no pain in the whole body. It was said that in the evening, it was hard and turned into green onion kimchi. One unit of the antiviral agent according to an embodiment of the present invention was taken twice a day for 4 weeks. This patient stated that from the 3rd day of taking, the body became lighter and the pain began to disappear, and from that moment on, there was no numbness or pain at all. This patient was suspected to have been infected with the virus in several parts of his body.
[임상시험 25] 만성손가락통증(58세, 남자)[Clinical trial 25] Chronic finger pain (58 years old, male)
1개월 전 우측 엄지 첫 마디를 사람에게 물려서 봉합 치료를 계속 하였는데 화농은 없고 콕콕 찌르는 통증이 발생하였고, 손목과 어깨도 근육통이 심하였다. 8년 전에도 동일부위를 같은 사람에게 물려서 80바늘의 봉합 치료를 하였다고 하였다. 1개월씩 계속 아픈데 화농이 없는 것은 바이러스 감염증이라고 판단하여, 본 발명의 실시 예에 따른 항바이러스제를 1 단위씩 하루에 두번 4주간 복용하게 하였다. 이 환자는, 4주후 통증과 근육통이 깨끗하게 사라졌다고 진술하였다. 통증과 근육통이 사라진 후에도 바이러스의 완치를 위하여 동일한 용량으로 5개월간 더 복용하게 하였다. One month ago, the first joint of the right thumb was bitten by a person and suture treatment was continued, but there was no suppuration and stabbing pain occurred, and the wrist and shoulder also suffered from severe muscle pain. Even 8 years ago, the same site was bitten by the same person and 80 stitches of suture treatment were performed. It was judged that it was a viral infection if there was no suppuration even though the pain continued for 1 month, and 1 unit of the antiviral agent according to an embodiment of the present invention was taken twice a day for 4 weeks. This patient stated that after 4 weeks the pain and myalgia had completely disappeared. Even after the pain and muscle pain disappeared, they were given the same dose for another 5 months to cure the virus.
[임상시험 26] 고혈압(53세, 남자)[Clinical trial 26] Hypertension (53 years old, male)
이 환자는 53세의 남자 환자로, 평소 고혈압이 있는데 혈압약을 먹으면 혈압이 너무 떨어져 불안정해지고, 어지럼증을 낀다고 호소하였다. 이 환자에게 본원 발명에 따른 항바이러스제를 1 단위씩 하루에 두번 3개월간 복용하게 하였다. 3개월 후 혈압약을 먹지 않고도 측정 혈압이 수축기 혈압 121mmHg, 확장기 혈압 81mmHg 부근으로 떨어진 상태를 꾸준히 유지하였다. 고혈압은 대표적인 생활습관 병으로 자극적인 음식, 비만, 운동부족, 과도한 스트레스 등으로 인해 발병하는 대표적인 질환이다. 본 발명자도 처음에는 고혈압을 바이러스성 질환으로 생각하지 못하였지만, 본원 발명에 따른 항바이러스제의 복용으로 혈압이 조절된 이러한 임상 사례를 통하여, 바이러스 감염이 몸 안의 특정 부위에 염증을 일으켜서 혈압을 올릴 수 있는 것으로 판단하게 되었다.This patient is a 53-year-old male patient. He usually has high blood pressure, but he complained that if he took blood pressure medication, his blood pressure dropped too much and he became unstable and had dizziness. This patient was instructed to take 1 unit of the antiviral agent according to the present invention twice a day for 3 months. After 3 months, the measured blood pressure dropped to around 121 mmHg in systolic blood pressure and 81 mmHg in diastolic blood pressure without taking blood pressure medication. Hypertension is a typical lifestyle-related disease that is caused by stimulant food, obesity, lack of exercise, and excessive stress. Although the present inventors did not initially think of hypertension as a viral disease, through these clinical cases in which blood pressure was controlled by taking the antiviral agent according to the present invention, viral infection can cause inflammation in a specific part of the body and raise blood pressure. was judged to be there.
[임상시험 27] 1형 당뇨(42세, 여자) [Clinical trial 27] Type 1 diabetes (42 years old, female)
이 환자는 당뇨가 심하여 발바닥 통증이 심하였던 환자이다. 매일 아침 일어나면 발바닥을 수십 개의 바늘로 찌르는 것처럼 심하게 아파서 바로 발을 바닥에 딛지 못하고 침대에 앉아서 한 시간 이상 주물러서 풀어야 걷는 것이 가능한 정도였다. 이 환자의 당뇨는 급성췌장염을 심하게 앓고 나서 발병한 1형 당뇨였다. 당시 인슐린을 아침저녁으로 주사하여도 식전혈당이 200mg/dℓ이하로 떨어지지 않고 식후 2시간 혈당은 더 높게 올라갔다. 또 갈증이 너무 심해서 혓바닥이 갈라질 정도이며 찬 물도 시원하지가 않아서 맥주를 냉동실에 얼려서 마시거나 얼음을 씹어 먹어야만 갈증이 풀리는 정도였다. 이 환자에게 찬물을 못 먹게 하고 체온보다 따뜻한 물만 먹게 하였으며, 매운 음식도 금하였다. 그렇게 1주일을 조절하니 그렇게 심하던 갈증이 사라졌고 혈당도 안정되기 시작하였다. 이는 찬 자극이 교감신경의 흥분을 유발하여 계속 혈당을 올리고 갈증을 유발하는 악순환의 고리에서 벗어난 것을 의미한다. 이후, 본 발명의 실시 예에 따른 항바이러스제를 적절하게(2 단위씩 하루에 두번 3개월간) 복용하게 하여, 인슐린 주사량을 아침에만 맞는 것으로 5단위까지 줄이게 되었다. 이 환자는, 본 발명의 실시 예에 따른 항바이러스제를 복용하는 과정에서 족부의 통증도 사라졌다고 진술하였으며, 족부의 염증도 점점 줄어드는 것이 관찰되었다. 이 환자를 통해, 1형 당뇨라도 인슐린 주사량을 줄일 수 있고 증상이 개선되는 것을 확인할 수 있었다. 이는 본 발명의 실시 예에 따른 항바이러스제로 췌장의 베타세포에 염증을 일으키는 바이러스를 박멸했기 때문인 것으로 판단했다. 인슐린 투여량이 줄어든 것은 췌장의 베타세포가 재생되어 활동하고 있다는 증거로 본다. 당뇨도 고혈압과 마찬가지로 대표적인 생활습관 병으로 자극적인 음식, 비만, 운동부족, 과도한 스트레스 등으로 인해 발병하는 대표적인 질환들이다. 본 발명자도 처음에는 당뇨를 바이러스성 질환으로 생각하지 못하였지만, 본 발명의 실시 예에 따른 항바이러스제의 복용으로 혈당이 조절된 임상 사례를 경험하면서, 당뇨를 바이러스가 몸 안의 특정 부위에 염증을 일으켜서 혈당을 올리는 질환으로 판단하게 되었다. This patient was diabetic and had severe foot pain. When I woke up every morning, it hurt so badly that I was stabbed in the soles of my feet with dozens of needles, so I couldn't put my feet on the floor right away. The diabetes of this patient was type 1 diabetes, which was developed after severe acute pancreatitis. At that time, even when insulin was injected in the morning and evening, the pre-meal blood sugar did not fall below 200 mg/dℓ, and the blood sugar rose higher 2 hours after a meal. Also, I was so thirsty that my tongue cracked, and the cold water wasn't cool, so I had to freeze the beer in the freezer or chew on ice to quench my thirst. The patient was not allowed to drink cold water, only water that was warmer than body temperature, and spicy food was also prohibited. After one week of control, the thirst disappeared and blood sugar began to stabilize. This means that cold stimulation causes excitability of the sympathetic nervous system, thereby breaking out of the vicious cycle of continuously raising blood sugar and causing thirst. Thereafter, the antiviral agent according to an embodiment of the present invention was appropriately taken (2 units twice a day for 3 months), and the insulin injection amount was reduced to 5 units only in the morning. This patient stated that the pain in the foot disappeared while taking the antiviral agent according to an embodiment of the present invention, and it was observed that the inflammation of the foot was also gradually reduced. Through this patient, it was confirmed that even with type 1 diabetes, the insulin injection amount could be reduced and symptoms improved. This was determined to be because the antiviral agent according to an embodiment of the present invention eradicated the virus causing inflammation in the beta cells of the pancreas. The decrease in insulin dose is regarded as evidence that the beta cells of the pancreas are regenerated and active. Diabetes, like high blood pressure, is a typical lifestyle disease that is caused by stimulant food, obesity, lack of exercise, and excessive stress. Although the present inventors did not initially think of diabetes as a viral disease, while experiencing clinical cases in which blood sugar was controlled by taking the antiviral agent according to an embodiment of the present invention, diabetes was caused by the virus causing inflammation in a specific part of the body. It was diagnosed as a disease that raises blood sugar.
[임상시험 28] 불임(31세, 여자)[Clinical trial 28] Infertility (31 years old, female)
이 환자는 불임을 치료하기 위해 직장까지 1년간 휴가를 내고 본격적으로 불임치료를 원하는 경우였다. 하지만 실제는 그녀의 체력이 너무 약해서 가벼운 일상생활조차 힘들어 하는 정도라 임신을 원하기보다는 체력을 보강하려는 마음이 간절하였다. 여성 불임인 경우는 산부인과 진단으로 특별한 원인이 없으면 여성생식기에 바이러스 감염으로 인한 염증이 심해서 임신이 안 되고 그로 인해 체력까지 고갈되어 임신상태를 유지할 여분의 체력이 없는 경우가 많다. 따라서 바이러스를 없애고 스스로 충분한 체력을 키운 후 임신이 되도록 돕는 치유방법을 권했고, 이 환자는 이를 받아들였다. 몸 상태로는 생리통이 심하고 아랫배가 차고 초음파 검사로는 자궁 상태가 깨끗하지 않다고 하였다. 피임을 하게 하고, 총 12개월간 본 발명의 실시 예에 따른 항바이러스제를 양을 조절해 가며 복용하게 한후, 12개월 후에 임신을 시도해도 좋다고 권하였다. 바로 그 주에 임신을 해서 아무런 문제없이 첫 아이를 건강하게 출산하고, 이후 추가 관리 없이 22개월 후에 둘째 아이를 건강하게 출산하였다. this patient It was a case of taking a year off from work to get treatment for infertility and wanting to receive infertility treatment in earnest. However, in reality, her physical strength was so weak that even light daily life was difficult. In the case of female infertility, if there is no specific cause due to the diagnosis of obstetrics and gynecology, the female genitals are inflamed due to viral infection, and pregnancy is not possible. Therefore, after getting rid of the virus and gaining sufficient physical strength, a healing method was recommended to help her become pregnant, and the patient accepted it. According to the physical condition, menstrual pain was severe, the lower abdomen was cold, and the state of the uterus was not clear by ultrasound examination. After using contraception and taking the antiviral agent according to an embodiment of the present invention in a controlled amount for a total of 12 months, it was recommended to try pregnancy after 12 months. She became pregnant that week and gave birth to her first child in good health without any problems, and after 22 months without any additional care, she gave birth to her second child.
[임상시험 29] 바이러스 진행성 뇌병변장애(9세, 남자)[Clinical trial 29] Viral progressive encephalopathy (9 years old, male)
갑자기 고열로 경기를 하여 삼성의료원에서 바이러스에 의한 진행성 뇌병변장애으로 진단받고 간질약을 복용 중인 환자였다. 증상은 인지능력과 운동능력의 저하를 동반하고 간혹 소발작을 하는 정도였다. 환자의 모친은 20년 넘게 앓아온 아토피 피부염(atopic dermatitis)을 본 발명자가 깨끗하게 낫도록 도와준 경험이 있어서 신뢰가 있는 보호자였다. 이 환자의 경우 이미 바이러스에 의한 뇌질환으로 진단을 받은 환자이므로 바이러스를 없애기 위해 초기 24개월간 본 발명의 실시 예에 따른 항바이러스제를 적절히 가감하면서 복용하게 하였다. 그 도중에 복용 중이었던 간질약을 줄여서 끊었음에도, 간질증상이 일어나지 않았으며, 지능과 운동능력도 정상으로 회복된 것이 관찰되었다. 또 23개월째에는 삼성의료원에서 시행하는 정기 뇌 검사에서 그동안 허옇게 보이던 바이러스 감염부위가 더 이상 나타나지 않는 것으로 확인되었다. The patient was diagnosed with a progressive brain lesion disorder caused by a virus at Samsung Medical Center because of a sudden high fever, and was taking antiepileptic drugs. The symptoms were accompanied by a decrease in cognitive and motor skills, and occasionally had minor seizures. The patient's mother was a trusted protector because she had experience helping the present inventors heal cleanly of atopic dermatitis, which had been suffering for over 20 years. Since this patient was already diagnosed with a brain disease caused by a virus, the antiviral agent according to the embodiment of the present invention was appropriately added or decreased for the first 24 months to eliminate the virus. It was observed that even if the epilepsy medication was reduced and stopped during the course, no epilepsy symptoms occurred, and the intelligence and motor ability recovered to normal. Also, at the 23rd month, it was confirmed that the virus-infected area, which had been blurry, no longer appeared in the regular brain examination conducted by Samsung Medical Center.
[임상시험 30] 뇌병변장애(7세, 여자)[Clinical trial 30] Brain lesion disorder (7 years old, female)
이 환자는 지적장애 2급으로 진단을 받은 여자 아이이다. 지적장애는 중추신경계의 바이러스성 뇌병변장애로 보고 24개월간 본 발명의 실시 예에 따른 항바이러스제를 투여량을 가감하면서 복용시켰다. 처음에는 제대로 걷지도 못하여 주변에서 손을 잡아줘야 하는 상황이고, 말도 못하고, 감정의 교류나 의사소통이 불가능하였다. 현재는 뛰기도 하고 두발을 모아 뛰기도 하며, 애교도 부리고, 샘도 부리는 정상 아이로 성장하고 있다. 이 경우에도 본 발명의 실시 예에 따른 항바이러스제에 의한 중추신경계의 염증을 일으키는 바이러스를 사멸시킨 것으로 판단한다. 지적 장애뿐만 아니라, 발달 장애, 발달지연, depression, ADHD(attention deficit hyperactivity disorder), 불면증, panic disorder, 강박증 등의 뇌병변장애 등의 신경계 질환들은 바이러스성 뇌병변장애의 경우와 달리 원인을 알 수는 없지만 바이러스성 뇌병변장애과 마찬가지로 바이러스가 중추신경계로 침입하여 뇌신경의 일부를 손상시키거나 기능을 제대로 하지 못하게 하는 경우에 해당한다고 본다. 또 병명이나 증상에 상관없이 원인이 모두 바이러스에 의한 중추신경염에서 진행된 질환이므로 필요한 처방은 모두 같고 단지 치유기간에서 차이를 보일 뿐이다. 또한 어릴 때 감염이 될수록 감염 정도에 비해 증상이 심하고 외형의 변화가 심할수록 치유기간이 늘어나는 것을 여러 임상 사례를 통해 확인하였다.This patient is a girl who was diagnosed with a grade 2 intellectual disability. Intellectual disability was regarded as a viral brain lesion disorder of the central nervous system, and the antiviral agent according to an embodiment of the present invention was administered while increasing or decreasing the dose for 24 months. At first, he could not walk properly, so he had to hold hands around him, and he could not speak, and it was impossible to exchange or communicate emotions. Currently, he is growing up as a normal child who can run, jump with his feet together, play aegyo, and play with Sam. Even in this case, it is determined that the virus causing inflammation of the central nervous system by the antiviral agent according to an embodiment of the present invention is killed. In addition to intellectual disability, neurological diseases such as developmental disability, developmental delay, depression, attention deficit hyperactivity disorder (ADHD), insomnia, panic disorder, and cerebral lesion disorders such as obsessive compulsive disorder, are different from viral encephalopathy. However, as with viral encephalopathy, the virus enters the central nervous system and damages a part of the cranial nerve or prevents it from functioning properly. In addition, regardless of the disease name or symptoms, the cause is a disease that has progressed from central neuritis caused by a virus, so the necessary prescriptions are the same, only the healing period is different. In addition, it has been confirmed through several clinical cases that the more the infection occurs at a young age, the more severe the symptoms compared to the degree of infection, and the more severe the change in appearance, the longer the healing period.
[임상시험 31] 발달장애(4세, 남자)[Clinical trial 31] Developmental disability (4 years old, male)
서울의료원 소아정신건강발달클리닉에서 관리 중인 환자였다. 서울의료원에서 실시한 심리교육검사결과는 실제연령- 3년2개월, 생활연령- 16개월, 발달지수(DQ)- 42.1이었다. 참고로 발달지수(DQ)는 아이큐와 비슷하게 100이 표준이고 100이상이면 발달이 앞서 있으며, 100 이하이면 늦은 것으로 볼 수 있다. 또 언어 지시 따르기, 착석 등 구조화된 환경에서의 과제 수행에 어려움을 보였으며 타인의 언어와 행동을 모방하거나 도전이나 반복이 필요한 문항 수행에서 제한적인 모습을 보였다는 의견이었다. 이 환자에게는 약 24개월간, 본 발명의 실시 예에 따른 항바이러스제를 복용량을 적절히 가감하면서 투여하였다. 그 결과, 심리교육검사 진전보고서에서는 실제연령- 4년 5개월, 생활연령- 4년 1개월, 발달지수(DQ)- 92.5로 많이 향상된 모습을 보였다. 또 일정시간 착석하기를 유지하여 과제에 집중할 수 있으며, 모방, 언어표현 등 타인과의 상호작용에 필요한 초보적인 사회성 기술과 지각, 소근육, 대근육, hand-eye coordination 및 동작성과 언어성 인지에 향상을 보이며 주의 집중 및 가위질, 선과 형태 그리기 등 기초학습기술과 재료 및 장난감에 대한 흥미 및 활용 등에 진전을 보였다.The patient was being managed at the Children's Mental Health Development Clinic at Seoul Medical Center. The results of the psychological education test conducted at Seoul Medical Center were actual age - 3 years and 2 months, living age - 16 months, and developmental index (DQ) - 42.1. For reference, the developmental index (DQ) is similar to IQ, where 100 is the standard, more than 100 is advanced development, and less than 100 is considered late. Another opinion was that they had difficulty performing tasks in a structured environment such as following language instructions and sitting, and that they had limited performance in items that imitate other people's language and behavior or that require challenge or repetition. For about 24 months, the antiviral agent according to an embodiment of the present invention was administered to this patient while appropriately increasing or decreasing the dose. As a result, in the progress report of the psychological education test, the actual age - 4 years and 5 months, the living age - 4 years and 1 month, the developmental index (DQ) - 92.5 showed a lot of improvement. In addition, it is possible to concentrate on the task by maintaining a seated position for a certain period of time, and to improve basic social skills necessary for interaction with others such as imitation and verbal expression, perception, fine muscle, large muscle, hand-eye coordination, and movement and verbal cognition. showed progress in basic learning skills such as concentration of attention, scissoring, drawing lines and shapes, and interest in and use of materials and toys.
[임상시험 32] 근디스트로피(Muscular Dystrophy)(5세, 남자)[Clinical Trial 32] Muscular Dystrophy (5 years old, male)
북경에 거주하는 중국인 아이로, 진행성 근디스트로피(Muscular Dystrophy)으로 진단을 받고 반년 넘게 중국 전역을 돌아다니며 치료의 가능성을 찾았지만 찾지 못한 상태에서 자포자기한 상태였던 환자이다. 본 발명의 실시 예에 따른 항바이러스제에 의한 치유 전에는 발육상태가 부진하고 30-50미터 정도 간신히 걸으면 힘들어서 쉬었다가 다시 걸어야 했다. 침대를 올라가려면 손에 힘이 없어서 손을 대고 오르지 못하고 먼저 머리를 침대에 대고 기어올라 가는 모습이었다. 유치원에서도 앉아 있지 못해서 수업에 참여하지 못하고 다른 아이들과도 어울리지 못하여 따로 놀았다고 하는 것으로 보아 지능저하도 동반한 경우이다. 다리를 만져보면 무릎 아래는 살이 없어서 뼈만 앙상하고 종아리에 조금 있는 근육도 돌처럼 단단하게 굳어있고 엉덩이 근육도 약간 굳어 있었다. 키도 82센티로 다른 아이들보다 작았다. 7개월간 본 발명의 실시 예에 따른 항바이러스제를 복용량을 가감하면서 복용하게 하였다. 7개월이 지난 후, 몇십 분을 걸을 수 있고, 부모 손을 잡고 가볍게 뛰며, 모듬발 뛰고, 침대에 손을 대고 오르며, 유치원에서도 수업시간에 잘 앉아서 수업에 참여하고 서툴지만 아이들과 어울리기도 한다. 다리는 엉덩이 근육은 정상이고 종아리에도 근육이 많이 생겨서 정상인과 별로 차이가 없어졌다. 또 종아리 근육 밑으로 돌처럼 단단하게 만져지던 것이 많이 풀렸지만 아직은 정상적이지 않은 단단함을 보이고 있다. 기적적인 것은 본 발명의 실시 예에 따른 항바이러스제를 복용하기 전에는 키가 82센티로 또래보다 많이 작은 키였는데 불과 7개월 사이에 109센티로 27센티나 커져서 오히려 다른 아이들 보다 커졌다. 이는 본래 자기 키의 약 1/3 정도를 자란 것으로 다리의 뭉친 근육이 뼈의 성장을 방해하다가 근육이 풀리고 건강상태가 좋아지면서 그동안 자라지 못한 키가 짧은 시간 자란 것으로 보인다. 근디스트로피(Muscular Dystrophy)은 유전성이고 진행성 근육병증으로 점진적인 근위축과 근쇠약이 나타나는 질환으로 알려져 왔으며, 현재까지 치료할 수 있는 특정한 방법은 없다. 유형에 따라 소아부터 성인 초기에 시작되고, 나이가 들수록 더욱 진행되어 보행이 힘들어지면서 척추후만곡증, 호흡 곤란 등이 나타나며, 심근에 이상이 발생하여 대부분의 생활을 침상에 의존하다가 동반된 폐렴이나 패혈증 등으로 사망하기도 한다. 하지만 안면견갑상완 근육퇴행위축과 같이 비교적 늦게 발병하고 진행이 느려 휠체어에 의존하게 되는 경우도 약 20% 정도 있다. 또한 유형에 따라 지능지수도 감소할 수 있으며, 호흡 근육이나 심근 침범으로 인한 호흡 부전 등으로 사망하게 되는 경우도 흔하다. 하지만 근디스트로피(Muscular Dystrophy) 환자를 관리하면서 환자의 상태가 확실하게 개선되는 결과를 확인하고 치료가 가능한 질환이고 또 바이러스질환이라고 판단하게 되었다. A Chinese child living in Beijing, who was diagnosed with progressive muscular dystrophy and had been looking for a cure for over half a year in China, but was in a desperate state. Before the treatment by the antiviral agent according to an embodiment of the present invention, the growth state was sluggish and it was difficult to walk about 30-50 meters, so I had to rest and walk again. To climb the bed, he was unable to climb with his hands because he had no strength in his hands. It is also a case of intellectual decline as it is said that they played separately because they could not participate in class because they could not sit in kindergarten, and they did not get along with other children. When I touched the leg, there was no flesh under the knee, only the bones were bare, and the muscles in the calf were hardened like stones, and the muscles of the buttocks were also slightly stiff. He was also 82 centimeters tall, shorter than the other children. For 7 months, the antiviral agent according to an embodiment of the present invention was taken while increasing or decreasing the dose. After 7 months, she can walk for a few dozen minutes, hop lightly while holding her parents' hands, hop on her feet, climb on the bed, sit well in class in kindergarten, participate in class, and get along with children even though she is clumsy. In the legs, hip muscles are normal and calves have a lot of muscle, so there is no difference from normal people. Also, a lot of things that were hard to touch like stones under the calf muscles have been loosened, but they are still showing a hardness that is not normal. Miraculously, before taking the antiviral agent according to an embodiment of the present invention, he was 82 cm tall, much shorter than his peers, but grew by 27 cm to 109 cm in just 7 months, rather than other children. This means that he has grown about 1/3 of his original height, and the cramped muscles in his legs hindered the growth of bones, but as the muscles loosened and his health improved, it seems that he had grown in a short period of time. Muscular dystrophy (Muscular Dystrophy) is a hereditary and progressive myopathy, which has been known as a disease in which progressive muscle atrophy and muscle weakness appear, and there is currently no specific method for treatment. Depending on the type, it starts from childhood to early adulthood, and it progresses more with age, causing difficulty in walking, resulting in kyphosis and breathing difficulties. may even die from However, about 20% of cases, such as facial scapulohumeral muscular dystrophy, have a relatively late onset and slow progression, leading to dependence on a wheelchair. Also, depending on the type, the IQ may decrease, and death is common due to respiratory failure due to invasion of the respiratory muscles or myocardium. However, while managing a patient with Muscular Dystrophy, the patient's condition was clearly improved, and it was determined that it was a treatable disease and a viral disease.
[임상시험 33] 묘성증후군(Cri du chat syndrome)(5세, 여자)[Clinical trial 33] Cri du chat syndrome (5 years old, female)
묘성증후군(Cri du chat syndrome)은, 고양이 울음소리와 비슷한 울음을 주증상으로 하는 염색체 이상으로 인한 선천적 질환이다. 묘성증후군(Cri du chat syndrome)은 1963년에 처음으로 보고되었으며, 5번째 염색체의 일부가 잘려나가 개체발생의 장애가 되고 후두발육이 불완전해지기 때문에 나타난다. 특징적인 증상은 고양이 울음소리와 비슷한 울음, 소두증, 지적장애 등이다. 그 밖의 증상으로는 둥근 얼굴, 넓은 미간, 근무력증, 손금 이상, 평발, 짧은 목 등이며 약 20%는 선천적 심장질환을 가지고 있다. 나이가 들면서 점차 고양이 울음소리, 근무력증, 둥근 얼굴 등이 없어질 수 있으며 특별한 치료법은 아직 없다. 이 환자는 본 발명의 실시 예에 따른 항바이러스제 복용전 상태는 전혀 의사소통이 안 되고, 타인과 어울리지도 못하여 따로 있고, 발육부진이 심하여 2살 어린 동생보다 키도 작고 몸무게도 적게 나가는 상태였다. 24개월간 본 발명의 실시 예에 따른 항바이러스제를 복용량을 적절히 가감하면서 복용하게 하였다. 복용 시작 후 발육이 좋아져서, 24개월 후에는 키가 동생보다 훨씬 커지고 몸무게도 많이 나가서 같은 사이즈의 옷을 입히지 못할 정도가 되었다. 또 이제는 사진을 찍자고 하면 포즈도 취해주고 타인과도 전에 비해 잘 어울린다고 한다. 이 경우에도 바이러스성 중추신경염으로 추측하는 뇌병변장애, 발달장애(developmental disorder), 발달지연과 같은 처방으로 개선되는 것이다. 이것으로부터, 묘성증후군(Cri du chat syndrome)은 치료가 가능한 질환이고, 또 바이러스질환인 것을 확인하였다.Cri du chat syndrome is a congenital disease caused by chromosomal abnormalities whose main symptom is crying similar to that of a cat. Cri du chat syndrome was first reported in 1963, and appears because a part of the fifth chromosome is cut off, which interferes with ontogenesis and causes incomplete laryngeal development. Characteristic symptoms include crying similar to that of a cat, microcephaly, and intellectual disability. Other symptoms include a round face, wide forehead, myasthenia gravis, anomalies in palms, flat feet, and a short neck, and about 20% of them have congenital heart disease. As you get older, your cat's cry, myasthenia gravis, and round face may gradually disappear, and there is no specific treatment yet. This patient was not able to communicate at all before taking the antiviral agent according to an embodiment of the present invention, and was not able to get along with others, so he had severe stunting, so he was shorter and weighed less than his two-year-old brother. For 24 months, the antiviral agent according to an embodiment of the present invention was taken while appropriately adjusting the dose. After I started taking it, my growth improved, and after 24 months, I was much taller than my brother and weighed a lot, so I couldn't wear clothes of the same size. Also, when they ask me to take a picture now, they pose for me and they say that I get along better with others than before. Even in this case, it will be improved with prescriptions such as brain lesion disorder, developmental disorder, and developmental delay presumed to be viral central neuritis. From this, it was confirmed that Cri du chat syndrome is a treatable disease and a viral disease.
[임상시험 34] 다운증후군(Down's syndrome)(12세, 여자)[Clinical trial 34] Down's syndrome (12 years old, female)
다운증후군(Down's syndrome)은 2개가 정상인 21번 염색체가 3개 존재하여 정신지체, 신체기형, 전신 기능 이상, 성장 장애 등을 일으키는 대표적인 유전질환이다. 신생아, 소아 시기부터 머리가 작으며, 둥글고 납작한 얼굴에 코가 낮고, 눈 꼬리가 올라가 있으며, 양 눈 사이가 멀어 보이는 등의 특징적인 안면 기형이 복합적으로 관찰된다. 목이 짧고 두꺼워 보이며 근육에 힘이 없다. 발달이 늦어 2세가 지나야 걸으며, 말도 늦어 결국 성인으로 성장한 후 평균 지능이 IQ 20~50 정도 된다. 키도 잘 자라지 않아서 성인이 되어도 키가 작으며 흔히 비만으로 관찰된다. 이 환자는 본 발명의 실시 예에 따른 항바이러스제가 다운증후군(Down's syndrome)을 치유할 수 있는지 확인하기 위해 2년간 본 발명의 실시 예에 따른 항바이러스제를 적용했던 환자이다. 본 발명의 실시 예에 따른 항바이러스제 적용 전에는 전형적인 다운증후군(Down's syndrome)의 모습이고, 지능 수준도 현재의 학년과 반을 이야기하는 것이 아니라 지난해의 학년과 반을 이야기할 정도로 인지능력이 많이 떨어지는 아이였다. 본 발명의 실시 예에 따른 항바이러스제를 복용량을 적절히 가감하면서 24개월간 복용하게 하면서, 복용시작 불과 4개월 만에 개선된 모습을 확인하였다. 다운증후군(Down's syndrome)의 특징 중 하나는 이마, 코, 입술이 일직선에 있는 것인데 턱이 들어가면서 이마, 코, 입술이 일직선에 있지 않고 코가 나오는 것을 사진으로 확인할 수 있었다. 이는 뇌부종으로 턱이 밀려나왔는데 뇌부종이 줄면서 턱이 정상으로 돌아간 것으로 생각된다. 또 그 과정에서 어깨와 목선이 줄고 대신 동시에 손가락이 특별히 자라는 모습을 확인할 수 있었다. 이는 어깨와 머리에 몰렸던 피가 사지로 내려가면서 변화되는 모습으로 생각된다. 다운증후군(Down's syndrome) 환자의 손가락은 짧고 손가락 끝이 갈수록 굵기가 급격하게 가늘어진다. 손가락이 자라는 모습은 개구리 발처럼 손끝이 둥글게 부풀어 오르다가 차츰 굵기가 동일해 지는 모습을 보였다. 24개월이 지난 후 지능수준도 많이 발달해서 보호자였던 할머니와 대화가 가능하고 잔소리를 할 정도로 발전하였다. 이를 통해, 다운증후군(Down's syndrome)이 바이러스성 중추신경염을 유발하여 다양한 외형적 신체변화를 가져오는 것으로 판단하게 되었다.Down's syndrome is a typical genetic disease that causes mental retardation, physical malformations, systemic dysfunction, and growth disorders due to the presence of three chromosomes 21, two of which are normal. Characteristic facial deformities such as a small head, a round and flat face, a low nose, raised tails of the eyes, and the distance between the eyes are observed from the newborn and childhood period. The neck is short and thick, and the muscles are weak. Its development is slow, and it walks only after 2 years of age, and it is slow to speak and eventually grows into an adult, with an average IQ of 20-50. He does not grow well, so he is short even when he becomes an adult, and is often observed as obese. This patient is a patient who has applied the antiviral agent according to the embodiment of the present invention for 2 years to check whether the antiviral agent according to the embodiment of the present invention can cure Down's syndrome. Before the application of the antiviral agent according to an embodiment of the present invention, it is a typical Down's syndrome, and the level of intelligence is not talking about the current grade and class, but about the grade and class of last year. it was While the antiviral agent according to an embodiment of the present invention was taken for 24 months while appropriately increasing or decreasing the dose, an improvement was confirmed in only 4 months from the start of taking. One of the characteristics of Down's syndrome is that the forehead, nose, and lips are in a straight line. It is thought that the jaw protruded due to cerebral edema, but as the cerebral edema decreased, the jaw returned to normal. Also, in the process, the shoulders and neckline decreased, and at the same time, it was confirmed that the fingers grew specially. This is thought to be a change in the form of blood flowing down from the shoulders and head to the extremities. Down's syndrome patients' fingers are short and the thickness of the fingertips is sharply tapered. As the finger grows, the tip of the finger swells up like a frog's foot, and then the thickness gradually becomes the same. After 24 months, the level of intelligence has also developed so much that he can talk with his grandmother, who was his guardian, and develop to the point of nagging. Through this, it was determined that Down's syndrome causes various external body changes by causing viral central neuritis.
<제조 판매 제품에 대한 효과 추적 결과><Results of tracking effects on manufactured and sold products>
출원인은 본 발명의 실시 예에 따른 항바이러스제 환을 약국을 통해 판매하고 있다. 판매에 참여한 약사들에 의해 투여 받은 환자들을 추적 관찰한 결과, 다음과 같은 증상 개선 효과를 확인하였다.The applicant is selling the antiviral pill according to an embodiment of the present invention through a pharmacy. As a result of follow-up of patients administered by pharmacists who participated in the sale, the following symptom improvement effects were confirmed.
1) 1,000명의 인플루엔자(influenza) 환자에 대한 투여 결과를 추적한 결과 925명(92.5%)의 환자에게서 증상 개선 효과를 확인하였다.1) As a result of tracking the administration results for 1,000 influenza patients, symptom improvement effects were confirmed in 925 (92.5%) patients.
2) 500명의 코감기(Rhinovirus) 환자에 대한 투여 결과를 추적한 결과 453명(90.6%)의 환자에게서 증상 개선 효과를 확인하였다.2) As a result of tracking the administration results for 500 Rhinovirus patients, symptom improvement effects were confirmed in 453 (90.6%) patients.
3) 100명의 대상포진(herpes zoster) 환자에 대한 투여 결과를 추적한 결과 91명(91%)에서 증상의 개선 효과를 확인하였다.3) As a result of tracking the administration results for 100 patients with herpes zoster, the improvement of symptoms was confirmed in 91 patients (91%).
4) 100명의 아토피 피부염(atopic dermatitis) 환자에 대한 투여 결과를 추적한 결과 88명(88%)에서 증상의 개선 효과를 확인하였다.4) As a result of tracking administration results for 100 patients with atopic dermatitis, improvement of symptoms was confirmed in 88 patients (88%).
5) 300명의 만성 비염 환자에 대한 투여 결과를 추적한 결과 243명(81%)에서 증상의 개선 효과를 확인하였다. 5) As a result of tracking the administration results for 300 chronic rhinitis patients, improvement of symptoms was confirmed in 243 patients (81%).
6) 100명의 건선(psoriasis) 환자에 대한 투여 결과를 추적한 결과 79명(79%)에서 증상의 개선 효과를 확인하였다.6) As a result of tracking the administration results for 100 psoriasis patients, improvement of symptoms was confirmed in 79 patients (79%).
7) 100명의 고혈압 환자에 대한 투여 결과를 추적한 결과 69명(69%)에서 증상의 개선 효과를 확인하였다.7) As a result of tracking the administration results for 100 hypertensive patients, improvement of symptoms was confirmed in 69 patients (69%).
8) 100명의 만성방광염 환자에 대한 투여 결과를 추적한 결과 55명(55%)에서 증상의 개선 효과를 확인하였다.8) As a result of tracking administration results for 100 chronic cystitis patients, improvement of symptoms was confirmed in 55 patients (55%).
9) 100명의 치주질환 환자에 대한 투여 결과를 추적한 결과 85명(85%)에서 증상의 개선 효과를 확인하였다.9) As a result of tracking the administration results for 100 patients with periodontal disease, improvement of symptoms was confirmed in 85 patients (85%).
10) 100명의 만성 근막질환 환자에 대한 투여 결과를 추적한 결과 43명(43%)에서 증상의 개선 효과를 확인하였다.10) As a result of tracking the administration results for 100 patients with chronic myofascial disease, improvement of symptoms was confirmed in 43 patients (43%).
Claims (1)
Maple syrup 1 to 11% by weight; 1 to 13% by weight of tabasheer, the sap of bamboo that is evaporated by strong heat in the process of making charcoal from bamboo; 20 to 40% by weight of yiyin; Xylitol 10-25% by weight; Vitamin C 1 to 8% by weight; Manuka honey 10-20% by weight; Frankincense 1 to 10% by weight; 1-10 wt% myrrh; An antiviral agent for the treatment or alleviation of rhinovirus containing 0.1 to 5% by weight of propolis.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220138994A KR102705550B1 (en) | 2018-04-21 | 2022-10-26 | Antiviral agent for treating or alleviating infectious gastroenteritis induced by transmissible gastroenteritis virus(tgev) |
KR1020220139006A KR102705552B1 (en) | 2018-04-21 | 2022-10-26 | Antiviral agent for treating or alleviating chronic gingivitis |
KR1020220139002A KR102705551B1 (en) | 2018-04-21 | 2022-10-26 | Antiviral agent for treating or alleviating encephalomyocarditis induced by encephalomyocarditis virus |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20180046429 | 2018-04-21 | ||
KR1020180046429 | 2018-04-21 | ||
KR1020190043428A KR20190122562A (en) | 2018-04-21 | 2019-04-14 | Antiviral agent and use thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190043428A Division KR20190122562A (en) | 2018-04-21 | 2019-04-14 | Antiviral agent and use thereof |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220139002A Division KR102705551B1 (en) | 2018-04-21 | 2022-10-26 | Antiviral agent for treating or alleviating encephalomyocarditis induced by encephalomyocarditis virus |
KR1020220139006A Division KR102705552B1 (en) | 2018-04-21 | 2022-10-26 | Antiviral agent for treating or alleviating chronic gingivitis |
KR1020220138994A Division KR102705550B1 (en) | 2018-04-21 | 2022-10-26 | Antiviral agent for treating or alleviating infectious gastroenteritis induced by transmissible gastroenteritis virus(tgev) |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20200024187A KR20200024187A (en) | 2020-03-06 |
KR102461669B1 true KR102461669B1 (en) | 2022-11-01 |
Family
ID=68462989
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190043428A KR20190122562A (en) | 2018-04-21 | 2019-04-14 | Antiviral agent and use thereof |
KR1020200023226A KR102461681B1 (en) | 2018-04-21 | 2020-02-25 | Pharmaceutical and food composition for treating or alleviating influenza a |
KR1020200023257A KR20200024186A (en) | 2018-04-21 | 2020-02-25 | Antiviral agent for treating or alleviating adenovirus |
KR1020200023264A KR102461669B1 (en) | 2018-04-21 | 2020-02-25 | Antiviral agent for treating or alleviating rhinovirus |
KR1020220139002A KR102705551B1 (en) | 2018-04-21 | 2022-10-26 | Antiviral agent for treating or alleviating encephalomyocarditis induced by encephalomyocarditis virus |
KR1020220138994A KR102705550B1 (en) | 2018-04-21 | 2022-10-26 | Antiviral agent for treating or alleviating infectious gastroenteritis induced by transmissible gastroenteritis virus(tgev) |
KR1020220139006A KR102705552B1 (en) | 2018-04-21 | 2022-10-26 | Antiviral agent for treating or alleviating chronic gingivitis |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190043428A KR20190122562A (en) | 2018-04-21 | 2019-04-14 | Antiviral agent and use thereof |
KR1020200023226A KR102461681B1 (en) | 2018-04-21 | 2020-02-25 | Pharmaceutical and food composition for treating or alleviating influenza a |
KR1020200023257A KR20200024186A (en) | 2018-04-21 | 2020-02-25 | Antiviral agent for treating or alleviating adenovirus |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220139002A KR102705551B1 (en) | 2018-04-21 | 2022-10-26 | Antiviral agent for treating or alleviating encephalomyocarditis induced by encephalomyocarditis virus |
KR1020220138994A KR102705550B1 (en) | 2018-04-21 | 2022-10-26 | Antiviral agent for treating or alleviating infectious gastroenteritis induced by transmissible gastroenteritis virus(tgev) |
KR1020220139006A KR102705552B1 (en) | 2018-04-21 | 2022-10-26 | Antiviral agent for treating or alleviating chronic gingivitis |
Country Status (1)
Country | Link |
---|---|
KR (7) | KR20190122562A (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230118955A1 (en) * | 2020-04-06 | 2023-04-20 | ManukaMed Limited Partnership | Viral treatments involving manuka honey and components thereof |
WO2021215938A1 (en) * | 2020-04-24 | 2021-10-28 | Oha Honey Limited Partnershp | Anti-viral methods and compositions |
KR102138654B1 (en) * | 2020-05-29 | 2020-07-28 | 김성재 | Antiviral composition comprising natural substance-derived substance and phytoncide |
KR102305665B1 (en) | 2020-08-10 | 2021-09-28 | (주)네이처페어리 | Antiviral or antibacterial compositions comprising Dendropanax morbiferus |
WO2023001919A1 (en) * | 2021-07-20 | 2023-01-26 | Christoph Von Keudell | Use of boswellia for treating sars-cov-2 infection |
WO2023038240A1 (en) * | 2021-09-10 | 2023-03-16 | 대한민국(농촌진흥청장) | Pharmaceutical composition for preventing or treating diseases caused by influenza a virus and enhancing immunity comprising castanea crenata sieb |
WO2024062228A1 (en) * | 2022-09-22 | 2024-03-28 | Mohamud Mohamud Adan | Composition comprising abutilon fruticosum, acacia nubica, acacia bussei and myrsine africana, methods of preparation and therapeutic uses |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009225685A (en) * | 2008-03-19 | 2009-10-08 | Kumamoto Technology & Industry Foundation | Brewage using adlay as raw material and method for producing the same |
JP2011042579A (en) * | 2007-12-17 | 2011-03-03 | Adept Co Ltd | Antiviral agent and method for treating antiviral agent |
JP2011046636A (en) * | 2009-08-26 | 2011-03-10 | Takex Labo:Kk | Antiviral composition and utilization thereof |
KR101627065B1 (en) * | 2015-01-22 | 2016-06-02 | 류형준 | Anti-influenza viral agent |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002072123A1 (en) * | 2001-03-02 | 2002-09-19 | Beppu, Kunihide | Preventives or remedies for tumor or papillomaviral diseases |
KR20010099494A (en) | 2001-10-09 | 2001-11-09 | 이영성, 권두한 | Novel extract from Agrimonia eupatoria L. inhibiting synthesis of surface antigen of hepatitis B virus, process for preparation the same and the use thereof |
JP4347543B2 (en) * | 2002-02-25 | 2009-10-21 | 株式会社ミック | Enriched maple syrup |
KR100558220B1 (en) * | 2004-03-10 | 2006-03-10 | 담양군 | A manufacturing process of the tabasheer for drinking purpose |
KR100904255B1 (en) * | 2007-09-28 | 2009-06-25 | 세명한방제약 주식회사 | Method for manufacturing a drink including Houttuynia cordata thunb and Saururus chinensis baill and the drink made by the same |
EP2697520B1 (en) * | 2011-04-12 | 2018-04-04 | R.P. Scherer Technologies, LLC | Capsules comprising an emulsified syrup and methods of making the same |
-
2019
- 2019-04-14 KR KR1020190043428A patent/KR20190122562A/en not_active Application Discontinuation
-
2020
- 2020-02-25 KR KR1020200023226A patent/KR102461681B1/en active IP Right Grant
- 2020-02-25 KR KR1020200023257A patent/KR20200024186A/en not_active Application Discontinuation
- 2020-02-25 KR KR1020200023264A patent/KR102461669B1/en active IP Right Grant
-
2022
- 2022-10-26 KR KR1020220139002A patent/KR102705551B1/en active IP Right Grant
- 2022-10-26 KR KR1020220138994A patent/KR102705550B1/en active IP Right Grant
- 2022-10-26 KR KR1020220139006A patent/KR102705552B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011042579A (en) * | 2007-12-17 | 2011-03-03 | Adept Co Ltd | Antiviral agent and method for treating antiviral agent |
JP2009225685A (en) * | 2008-03-19 | 2009-10-08 | Kumamoto Technology & Industry Foundation | Brewage using adlay as raw material and method for producing the same |
JP2011046636A (en) * | 2009-08-26 | 2011-03-10 | Takex Labo:Kk | Antiviral composition and utilization thereof |
KR101627065B1 (en) * | 2015-01-22 | 2016-06-02 | 류형준 | Anti-influenza viral agent |
Non-Patent Citations (1)
Title |
---|
빗소리완영, 메이플시럽을 아시나요 ^^, 다음 카페(2016.06.21.) 1부.* |
Also Published As
Publication number | Publication date |
---|---|
KR20190122562A (en) | 2019-10-30 |
KR20230005783A (en) | 2023-01-10 |
KR102705550B1 (en) | 2024-09-11 |
KR102705552B1 (en) | 2024-09-11 |
KR20220165674A (en) | 2022-12-15 |
KR20200024186A (en) | 2020-03-06 |
KR102461681B1 (en) | 2022-11-01 |
KR20230006765A (en) | 2023-01-11 |
KR102705551B1 (en) | 2024-09-11 |
KR20200024185A (en) | 2020-03-06 |
KR20200024187A (en) | 2020-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102461669B1 (en) | Antiviral agent for treating or alleviating rhinovirus | |
Ghosh et al. | Management of snake bite in India | |
Glöckler | A guide to child health: A holistic approach to raising healthy children | |
Akanchi et al. | Systematic Investigations of the Healing Process of Skin, Oral and Dental Wounds and Cardiac and Pulmonary Complications and Drug Therapy in Patients with Infectious Diseases | |
Rostami et al. | Diagnosis And Treatment Of Guillain-Barre Syndrome And Neurological Problems With A Clinical Approach: A Systematic Review | |
Shoko | Karanga traditional medicine and healing | |
CN107320674A (en) | A kind of Chinese medicine composition and its application | |
US10959450B2 (en) | Food composition for relieving symptoms of allergic and autoimmune diseases | |
Keet | The Reflexology Bible: Godsfield Bibles | |
KR102077833B1 (en) | Fuctional food compositions | |
KR20190044823A (en) | Composition for treating muscular skeletal disease | |
Niraj et al. | A case study on the ayurvedic management of spastic cerebral palsy due to birth asphyxia | |
Shreeve | Alternative Dictionary Of Symptoms And Cures: A Comprehensive Guide to Diseases and Their Orthodox and Alternative Remedies | |
Glöckler et al. | A Waldorf Guide to Children's Health: Illnesses, Symptoms, Treatments and Therapies | |
TW201121562A (en) | Compositions of Clerodendrum sp. for treating tic disorders or psychiatric disorders with sensorimotor gating deficits | |
Roberts | Tissue Salts for Healthy Living | |
Aliaga | The secrets of pain relief: Natural remedies that will end your suffering | |
Akanchi et al. | Systematic Investigations of Neurological, Cardiac and Dental Problems in Patients with Infectious and other Problems, Hospitalization &Types of nutrition in the Special Care Unit With Drug Delivery in Patients | |
Budanova et al. | Essential Pharmacy English in Use (for French and Russian speaking international students) Part I: non-chemical subjects | |
Axe et al. | The Essential Oils Home Remedy Guide | |
Monjoghtapeh et al. | Principles Of Treatment Staff Care For Patients With Diabetes, Chronic Abdominal Pain And Hypertention In ICU Based On Pharmacology And Radiological Points: A Systematic Review | |
Su | THERAPEUTIC SOLUTIONS FOR COVID | |
Keet | The reflexology bible: the definitive guide to pressure point healing | |
Clark et al. | What's the Alternative?: Orthodox and Complementary Remedies for Common Complaints | |
CN116077574A (en) | Medicine for treating rheumatism bone diseases and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) |